Methods of using interleukin-10 for treating diseases and disorders

ABSTRACT

Methods of modulating immune responses in subjects having oncology- and immune-related diseases, disorders and conditions by the administration of an IL-10 agent, including pegylated IL-10.

CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority benefit of U.S. provisionalapplication Ser. No. 62/167,699, filed May 28, 2015, which applicationis incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention relates to methods of using IL-10 agents to modulateimmune responses in the treatment or prevention of oncology- andimmune-related diseases, disorders and conditions.

INTRODUCTION

The cytokine interleukin-10 (IL-10) is a pleiotropic cytokine thatregulates multiple immune responses through actions on T cells, B cells,macrophages, and antigen presenting cells (APC). IL-10 can suppressimmune responses by inhibiting expression of IL-1α, IL-1β, IL-6, IL-8,TNF-α, GM-CSF and G-CSF in activated monocytes and activatedmacrophages, and it also suppresses IFN-γ production by NK cells.Although IL-10 is predominantly expressed in macrophages, expression hasalso been detected in activated T cells, B cells, mast cells, andmonocytes. In addition to suppressing immune responses, IL-10 exhibitsimmuno-stimulatory properties, including stimulating the proliferationof IL-2- and IL-4-treated thymocytes, enhancing the viability of Bcells, and stimulating the expression of MHC class II.

Human IL-10 is a homodimer that becomes biologically inactive upondisruption of the non-covalent interactions between the two monomersubunits. Data obtained from the published crystal structure of IL-10indicates that the functional dimer exhibits certain similarities toIFN-γ (Zdanov et al, (1995) Structure (Lond) 3:591-601).

As a result of its pleiotropic activity, IL-10 has been linked to abroad range of diseases, disorders and conditions, includinginflammatory conditions, immune-related disorders, fibrotic disorders,metabolic disorders and cancer. Clinical and pre-clinical evaluationswith IL-10 for a number of such diseases, disorders and conditions havesolidified its therapeutic potential. Moreover, pegylated IL-10 has beenshown to be more efficacious than non-pegylated IL-10 in certaintherapeutic settings.

SUMMARY

The present disclosure contemplates the use of an IL-10 agent (e.g.,pegylated IL-10) as a component of chimeric antigen receptor-T celltherapy (CAR-T cell therapy). CARs represent an emerging therapy forcancer (e.g., treatment of B and T cell lymphomas) and othermalignancies. CAR-T T cells generally comprise patient-derived memoryCD8+ T cells modified to express a recombinant T cell receptor specificfor a known antigen present on, for example, a tumor of interest. Whilethe present disclosure is generally described in the context of usingCAR-T cell therapy for the treatment of cancer, it is to be understoodthat such therapy is not so limited.

CAR-T T cell therapy comprises use of adoptive cell transfer (ACT), aprocess which utilizes a patient's own cultured T cells. In CAR-T celltherapy, T cells are removed from a patient and genetically altered toexpress CARs directed towards antigens specific for a known cancer(e.g., a tumor). Following amplification ex vivo to a sufficient number,the autologous cells are infused back into the patient, resulting in theantigen-specific destruction of the cancer. In this manner, CAR-T T celltherapy is similar to apheresis in which blood taken from a patient istreated in a manner that separates out one particular constituent (e.g.,removal of malignant white blood cells in the process ofleukocytapheresis) and then the remainder is returned to the patient'scirculation.

As discussed further hereafter, treatment with CAR-T cell therapy has,in part, been limited by both the induction of antigen-specifictoxicities targeting normal tissues expressing the target-antigen, andthe extreme potency of CAR-T cell treatments resulting inlife-threatening cytokine-release syndromes. In particular, it has beenobserved that high affinity T cell receptor interactions withsignificant antigen burden can lead to activation-induced cell death.Historically, the scientific literature has discussed IL-10 in thecontext of enhancement of activation-induced cell death (Georgescu etal. (1997) J Clin Invest 100(10):2622-33). However, the data presentedherein suggest that an IL-10 agent may be used in conjunction with CAR-TT cell therapy to prevent or limit activation-induced cell death whileenhancing CD8+ T cell function and survival.

As discussed further hereafter, human IL-10 is a homodimer, and eachmonomer comprises 178 amino acids, the first 18 of which comprise asignal peptide. Particular embodiments of the present disclosurecomprise mature human IL-10 polypeptides lacking the signal peptide(see, e.g., U.S. Pat. No. 6,217,857), or mature human PEG-IL-10. Infurther particular embodiments, the IL-10 agent is a variant of maturehuman IL-10. The variant can exhibit activity less than, comparable to,or greater than the activity of mature human IL-10; in certainembodiments the activity is comparable to or greater than the activityof mature human IL-10.

Certain embodiments of the present disclosure contemplate modificationof IL-10 in order to enhance one or more properties (e.g.,pharmacokinetic parameters, efficacy, etc.). Such IL-10 modificationsinclude pegylation, glycosylation, albumin (e.g., human serum albumin(HSA)) conjugation and fusion, and hesylation. In particularembodiments, IL-10 is pegylated. In further embodiments, modification ofIL-10 does not result in a therapeutically relevant, detrimental effecton immunogenicity, and in still further embodiments modified IL-10 isless immunogenic than unmodified IL-10. The terms “IL-10”, “IL-10polypeptide(s),” “agent(s)” and the like are intended to be construedbroadly and include, for example, human and non-human IL-10-relatedpolypeptides, including homologs, variants (including muteins), andfragments thereof, as well as IL-10 polypeptides having, for example, aleader sequence (e.g., the signal peptide), and modified versions of theforegoing. In further particular embodiments, the terms “IL-10”, “IL-10polypeptide(s), “agent(s)” are agonists. Particular embodiments relateto pegylated IL-10, which is also referred to herein as “PEG-IL-10”. Thepresent disclosure also contemplates nucleic acid molecules encoding theforegoing, vectors and the like containing the nucleic acid molecules,and cells (e.g., transformed cells and host cells) that express theIL-10 agents.

The present disclosure contemplates methods of using CAR-T cell therapyand an IL-10 agent to modulate a T cell-mediated immune response to atarget cell population in a subject. A particular embodimentcontemplates a method of modulating a T cell-mediated immune response toa target cell population in a subject, comprising a) introducing to thesubject a therapeutically effective plurality of cells geneticallymodified to express a chimeric antigen receptor, wherein the chimericantigen receptor comprises at least one antigen-specific targetingregion capable of binding to the target cell population, and wherein thebinding of the chimeric antigen receptor targeting region to the targetcell population is capable of eliciting activation-induced cell death;and b) administering to the subject a therapeutically effective amountof an IL-10 agent sufficient to prevent or limit the activation-inducedcell death. In particular embodiments, the CAR comprises an antigenbinding domain which specifically recognizes the target cell population.

In certain embodiments of the present disclosure, the IL-10 agentenhances the function of activated memory CD8+ T cells. In otherembodiments, the amount of the IL-10 agent administered is sufficient toenhance cytotoxic function.

Embodiments are contemplated wherein administration of the IL-10 agentis prior to, simultaneously with, or subsequent to administration of thetherapeutically effective plurality of cells. In certain embodiments ofthe present disclosure, the IL-10 agent is administered subcutaneously.

In certain embodiments, the present disclosure contemplates theadministration of the IL-10 agent in an amount sufficient to achieve aserum concentration of from 10 to 100 ng/mL. In some embodiments, theIL-10 agent is administered to a subject in an amount sufficient tomaintain a mean IL-10 serum trough concentration of from 1 pg/mL to 10.0ng/mL. In some embodiments, the mean IL-10 serum trough concentration offrom 1.0 pg/mL to 10.0 ng/mL is maintained for at least 95% of a definedperiod of time. In further embodiments of the present disclosure, themean IL-10 serum trough concentration is in the range of from 1.0 pg/mLto 100 pg/mL; from 0.1 ng/mL to 1.0 ng/mL; from 1.0 ng/mL to 10 ng/mL;from 0.5 ng/mL to 5.0 ng/mL; from 0.75 ng/mL to 1.25 ng/mL or from 0.9ng/mL to 1.1 ng/mL. In particular embodiments of the present disclosure,the mean IL-10 serum trough concentration is at least 1.25 ng/mL, atleast 1.5 ng/mL, at least 1.6 ng/mL, at least 1.7 ng/mL, at least 1.8ng/mL, at least 1.85 ng/mL, at least 1.9 ng/mL, at least 1.95 ng/mL, atleast 1.97 ng/mL, and least 1.98 ng/mL, at least 1.99 ng/mL, at least2.0 ng/mL or greater than 2 ng/mL.

In further embodiments, the aforementioned period of time is at least 12hours, at least 24 hours, at least 48 hours, at least 72 hours, at least1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 6weeks, at least 2 months, at least 3 months, at least 6 months, at least9 months, or greater than 12 months.

In particular embodiments of the present disclosure, the mean IL-10serum trough concentration is maintained for at least 85% of the periodof time, at least 90%, at least 96%, at least 98%, at least 99% or 100%of the period of time.

It is envisaged that a dosing regimen sufficient to maintain a desiredsteady state serum trough concentration (e.g., 1 ng/mL) can result in aninitial serum trough concentration that is higher than the desiredsteady state serum trough concentration. Because of the pharmacodynamicand pharmacokinetic characteristics of IL-10 in a mammalian subject, aninitial trough concentration (achieved, for example, through theadministration of one or more loading doses followed by a series ofmaintenance doses) gradually but continually decreases over a period oftime even when the dosing parameters (e.g., amount and frequency) arekept constant. After that period to time, the gradual but continualdecrease ends and a steady state serum trough concentration ismaintained.

By way of example, parenteral administration (e.g., SC and IV) of ˜0.1mg/kg/day of an IL-10 agent (e.g., mIL-10) to a mouse (e.g., a C57BL/6mouse) is required to maintain a steady state serum trough concentrationof 2.0 ng/mL. However, that steady state serum trough concentrationcannot be achieved until approximately 30 days after initiation ofdosing at 0.1 mg/kg/day (and also after any loading dose(s)). Rather,after an initial serum trough concentration has been achieved (e.g., 2.5ng/mL), that concentration gradually but continually decreases over thecourse of, for example, the approximately 30-day period, after whichtime the desired steady state serum trough concentration (2.0 ng/mL) ismaintained. One of skill in the art will be able to determine the doseneeded to maintain the desired steady state trough concentration using,for example, ADME and patient-specific parameters.

The present disclosure contemplates methods wherein the IL-10 agentcomprises at least one modification to form a modified IL-10 agent,wherein the modification does not alter the amino acid sequence of theIL-10 agent. In some embodiments, the modified IL-10 agent is aPEG-IL-10 agent. The PEG-IL-10 agent can comprise at least one PEGmolecule covalently attached to at least one amino acid residue of atleast one subunit of IL-10 or comprise a mixture of mono-pegylated anddi-pegylated IL-10 in other embodiments. The PEG component of thePEG-IL-10 agent can have a molecular mass greater than about 5 kDa,greater than about 10 kDa, greater than about 15 kDa, greater than about20 kDa, greater than about 30 kDa, greater than about 40 kDa, or greaterthan about 50 kDa. In some embodiments, the molecular mass is from about5 kDa to about 10 kDa, from about 5 kDa to about 15 kDa, from about 5kDa to about 20 kDa, from about 10 kDa to about 15 kDa, from about 10kDa to about 20 kDa, from about 10 kDa to about 25 kDa or from about 10kDa to about 30 kDa.

In some embodiments, the modified IL-10 agent comprises at least one Fcfusion molecule, at least one serum albumin (e.g., HSA or BSA), an HSAfusion molecule or an albumin conjugate. In additional embodiments, themodified IL-10 agent is glycosylated, is hesylated, or comprises atleast one albumin binding domain. Some modified IL-10 agents cancomprise more than one type of modification. In particular embodiments,the modification is site-specific. Some embodiments comprise a linker.Modified IL-10 agents are discussed in detail hereafter.

The present disclosure also contemplates the use of CAR-T cell therapyfor the treatment or prevention of a disease, disorder or condition(e.g., a cancer-related disorder) in a subject in conjunction with theintroduction to the subject of cells genetically modified to express anIL-10 agent. Due to its the direct and local effect, the amount of theIL-10 agent secreted from such cells that is necessary to dampen theinduction of antigen-specific toxicities targeting normal tissuesexpressing the target-antigen, and the extreme potency of CAR-T celltreatments resulting in life-threatening cytokine-release syndromes, ismuch less than the amount of an IL-10 agent administered to a subject ina conventional manner (e.g., subcutaneously). Indeed, the amount of thesecreted IL-10 agent necessary to achieve the aforementioned effects maybe undetectable in the serum.

In some such embodiments, the present disclosure contemplates a methodof modulating a T cell-mediated immune response to a target cellpopulation in a subject, comprising introducing to the subject atherapeutically effective plurality of cells genetically modified toexpress a) a chimeric antigen receptor, wherein the chimeric antigenreceptor comprises at least one antigen-specific targeting regioncapable of binding to the target cell population, and wherein thebinding of the chimeric antigen receptor targeting region to the targetcell population is capable of eliciting activation-induced cell death;and b) an IL-10 agent in an amount sufficient to prevent or limit theactivation-induced cell death.

In some embodiments, the chimeric antigen receptor and the IL-10 agentare expressed by the same vector, while in other embodiments thechimeric antigen receptor and the IL-10 agent are expressed by differentvectors. In particular embodiments, the therapeutically effectiveplurality of cells is transfected with a vector that expresses the IL-10agent in an amount sufficient to enhance cytotoxic function. The vectormay be, for example, a plasmid or a viral vector. The present disclosurealso contemplates the use of any other means of expressing the IL-10agent. In particular embodiments, expression of the IL-10 agent ismodulated by an expression control element.

In the embodiments described above, the plurality of cells may beobtained from the subject and genetically modified ex vivo. Theplurality of cells is obtained from the subject by an aphaeretic processin some embodiments. In other embodiments of the present disclosure, theplurality of cells is memory CD8+ T cells, while in still otherembodiments they are autologous tumor cells.

The present disclosure contemplates methods of modulating a Tcell-mediated immune response to a target cell population in a subject,comprising introducing to the subject a) a therapeutically effectivefirst plurality of cells genetically modified to express a chimericantigen receptor, wherein the chimeric antigen receptor comprises atleast one antigen-specific targeting region capable of binding to thetarget cell population, and wherein the binding of the chimeric antigenreceptor targeting region to the cell population is capable of elicitingactivation-induced cell death; and b) a therapeutically effective secondplurality of cells genetically modified to express an IL-10 agent in anamount sufficient to prevent or limit the activation-induced cell death.

In particular embodiments, the therapeutically effective plurality ofcells is transfected with a vector that expresses the IL-10 agent in anamount sufficient to enhance cytotoxic function. The therapeuticallyeffective second plurality of cells comprises CD8+ T cells transfectedwith a vector that expresses the IL-10 agent in still other embodiments.

In particular embodiments, the first plurality of cells is obtained fromthe subject and genetically modified ex vivo, while in other embodimentsthe second plurality of cells is obtained from the subject andgenetically modified ex vivo. The present disclosure contemplatesembodiments wherein the first plurality of cells and the secondplurality of cells are obtained from the subject by an aphaereticprocess. In some embodiments, the first plurality of cells is memoryCD8+ T cells, and the second plurality of cells is naïve CD8+ T cells.The first plurality of cells and the second plurality of cells areautologous tumor cells in still other embodiments.

In each of the aforementioned embodiments, the target cell populationmay comprise a tumor antigen. Vigneron, N. et al. ((15 Jul. 2013) CancerImmunity 13:15) describe a database of T cell—defined human tumorantigens containing over 400 tumor antigenic peptides. Examples of tumorantigens include, but are not limited to, CD19, CD20, CD22, ROR1,mesothelin, CD33/IL3Ra, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2,NY-ESO-1 TCR, MAGE A3 TCR, or any combination thereof.

The present disclosure also contemplates the use of CAR-T cell therapyfor the treatment or prevention of a disease, disorder or condition(e.g., a cancer-related disorder) in a subject in combination with theadministration of an IL-10 agent (e.g., PEG-IL-10) or the introductionof a vector that expresses an IL-10 agent.

A particular embodiment comprises methods of treating a subject having acancer-related disease, disorder or condition (e.g., a tumor),comprising a) introducing to the subject a therapeutically effectiveplurality of cells genetically modified to express a chimeric antigenreceptor, wherein the chimeric antigen receptor comprises at least oneantigen-specific targeting region capable of binding to the target cellpopulation, and wherein the binding of the chimeric antigen receptortargeting region to the target cell population is capable of elicitingactivation-induced cell death; and b) administering to the subject atherapeutically effective amount of an IL-10 agent sufficient to preventor limit the activation-induced cell death. In particular embodiments,the subject being treated has an immune-related disease, disorder orcondition or another disease, disorder or condition described herein.

In certain embodiments of the present disclosure, such methods are usedin therapeutic protocols for the prevention of a cancer-related disease,disorder or condition in a subject, while in other embodiments suchmethods are used in therapeutic protocols for the prevention ofimmune-related disorders. Further aspects of the above-describedmethods, including dosing parameters and regimens for the IL-10 agentsas well as exemplary types of such agents, are described elsewhereherein.

Additional embodiments of the present disclosure contemplate methods oftreating a subject having a cancer-related disease, disorder orcondition, comprising introducing to the subject a therapeuticallyeffective plurality of cells genetically modified to express a) achimeric antigen receptor, wherein the chimeric antigen receptorcomprises at least one antigen-specific targeting region capable ofbinding to the target cell population, and wherein the binding of thechimeric antigen receptor targeting region to the target cell populationis capable of eliciting activation-induced cell death; and b) an IL-10agent in an amount sufficient to prevent or limit the activation-inducedcell death.

In some embodiments, the chimeric antigen receptor and the IL-10 agentare expressed by the same vector, while in other embodiments thechimeric antigen receptor and the IL-10 agent are expressed by differentvectors. In particular embodiments, the therapeutically effectiveplurality of cells is transfected with a vector that expresses the IL-10agent in an amount sufficient to enhance cytotoxic function. The vectormay be, for example, a plasmid or a viral vector. The present disclosurealso contemplates the use of any other means of expressing the IL-10agent. In particular embodiments, expression of the IL-10 agent ismodulated by an expression control element.

In the embodiments described above, the plurality of cells may beobtained from the subject and genetically modified ex vivo. According tothe present disclosure, the plurality of cells is obtained from thesubject by an aphaeretic process in some embodiments. The plurality ofcells is memory CD8+ T cells in particular embodiments, and isautologous tumor cells in other embodiments.

The present disclosure contemplates methods wherein the IL-10 agent isexpressed in an amount sufficient to prevent or limit theactivation-induced cell death at least one week after introduction tothe subject. In other particular embodiments, the IL-10 agent isexpressed in an amount sufficient to prevent or limit theactivation-induced cell death at least two weeks, at least three weeks,at least one month, at least two months, at least three months, at leastfour months, at least five months, at least six months, at least sevenmonths, at least eight months, at least nine months, or at least oneyear or more, after introduction to the subject.

Still further embodiments of the present disclosure contemplate methodsof treating a subject having a cancer-related disease, disorder orcondition, comprising introducing to the subject a) a therapeuticallyeffective first plurality of cells genetically modified to express achimeric antigen receptor, wherein the chimeric antigen receptorcomprises at least one antigen-specific targeting region capable ofbinding to the target cell population, and wherein the binding of thechimeric antigen receptor targeting region to the target cell populationis capable of eliciting activation-induced cell death; and b) atherapeutically effective second plurality of cells genetically modifiedto express an IL-10 agent in an amount sufficient to prevent or limitthe activation-induced cell death. Examples of the lengths of time whichthe IL-10 agent is expressed in an amount sufficient to prevent or limitthe activation-induced cell death are described elsewhere herein.

In certain embodiments, the methods described above are used intherapeutic protocols for the prevention of a disease, disorder orcondition, including a cancer- or an immune-related disease, disorder orcondition in a subject.

The present disclosure contemplates methods wherein the IL-10 agent isexpressed in an amount sufficient to prevent or limit theactivation-induced cell death for periods of time described elsewhereherein.

In particular embodiments, the therapeutically effective first pluralityof cells is transfected with a vector that expresses the IL-10 agent inan amount sufficient to enhance cytotoxic function. The therapeuticallyeffective second plurality of cells comprises CD8+ T cells transfectedwith a vector that expresses the IL-10 agent in still other embodiments.

In particular embodiments, the first plurality of cells is obtained fromthe subject and genetically modified ex vivo, while in other embodimentsthe second plurality of cells is obtained from the subject andgenetically modified ex vivo. The present disclosure contemplatesembodiments wherein the first plurality of cells and the secondplurality of cells are obtained from the subject by an aphaereticprocess. In some embodiments, the first plurality of cells is memoryCD8+ T cells, and the second plurality of cells is naïve CD8+ T cells.The first plurality of cells and the second plurality of cells areautologous tumor cells in still other embodiments.

In each of the aforementioned embodiments, the target cell populationmay comprise a tumor antigen, examples of which are described elsewhereherein.

The present disclosure contemplates nucleic acid molecules that encodethe IL-10 agents described herein. In certain embodiments, a nucleicacid molecule is operably linked to an expression control element thatconfers expression of the nucleic acid molecule encoding the IL-10agent. In some embodiments, a vector (e.g., a plasmid or a viral vector)comprises the nucleic acid molecule. Also contemplated herein aretransformed or host cells that express the IL-10 agent.

In still further embodiments, the present disclosure provides methods ofenhancing the function of a CAR-T T cell, comprising a) geneticallyengineering a T cell to express a CAR, thereby generating a CAR-T Tcell; and b) modulating the CAR-T T cell with an agent (e.g., a smallinterfering RNA (siRNA)) that reduces the amount of at least onecytokine secreted by the CAR-T T cell. Examples of cytokines include,but are not limited to, members of the tumor necrosis factor family orthe transforming growth factor beta superfamily (e.g., TGF-β).Embodiments are contemplated wherein reducing the amount of TGF-βreduces the proliferation of T regulatory cells.

Other embodiments will be apparent to the skilled artisan based on theteachings of the present disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the fold-increase of PD-1 and LAG3+ peripheral T cellsafter 29 days of treatment with PEG-rHuIL-10.

FIG. 2 indicates that PEG-IL-10 preferentially enhances IFNγ productionin memory CD8+T cells (CD45RO+) compared to naïve CD8+ T cells.

FIG. 3 indicates that PEG-IL-10 is capable of limitingactivation-induced cell death in CD8+T cells (CD45RO+).

DETAILED DESCRIPTION

Before the present disclosure is further described, it is to beunderstood that the disclosure is not limited to the particularembodiments set forth herein, and it is also to be understood that theterminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range and any other stated or intervening value in thatstated range, is encompassed within the invention. The upper and lowerlimits of these smaller ranges can independently be included in thesmaller ranges, and are also encompassed within the invention, subjectto any specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention. Unlessdefined otherwise, all technical and scientific terms used herein havethe same meaning as commonly understood by one of ordinary skill in theart to which this invention belongs.

It must be noted that as used herein and in the appended claims, thesingular forms “a,” “an,” and “the” include plural referents unless thecontext clearly dictates otherwise. It is further noted that the claimsmay be drafted to exclude any optional element. As such, this statementis intended to serve as antecedent basis for use of such exclusiveterminology such as “solely,” “only” and the like in connection with therecitation of claim elements, or use of a “negative” limitation.

The publications discussed herein are provided solely for theirdisclosure prior to the filing date of the present application. Further,the dates of publication provided may be different from the actualpublication dates, which may need to be independently confirmed.

Overview

CAR-T T cell therapy is a promising therapeutic approach for, forexample, the treatment of cancer-related (e.g., B and T cell lymphomas)and immune-related malignancies. CAR-T T cells generally comprisepatient-derived memory CD8+ T cells modified to express a recombinant Tcell receptor specific for a known antigen present on, for example, atumor of interest. While the present disclosure is generally describedin the context of using CAR-T cell therapy for the treatment of cancer,it is to be understood that such therapy also finds utility in thetreatment of other indications.

As discussed further herein, when CAR-T cell therapy has been used inthe treatment of certain cancers (e.g., non-B cell malignancies), highaffinity T cell receptor interactions with significant antigen burdenhave been observed that can lead to activation-induced cell death.Although IL-10 has previously been linked to the enhancement ofactivation-induced cell death, the data presented herein suggest that anIL-10 agent may be used in conjunction with CAR-T T cell therapy toprevent or limit activation-induced cell death while enhancing CD8+ Tcell function and survival.

It should be noted that any reference to “human” in connection with thepolypeptides and nucleic acid molecules of the present disclosure is notmeant to be limiting with respect to the manner in which the polypeptideor nucleic acid is obtained or the source, but rather is only withreference to the sequence as it can correspond to a sequence of anaturally occurring human polypeptide or nucleic acid molecule. Inaddition to the human polypeptides and the nucleic acid molecules whichencode them, the present disclosure contemplates IL-10-relatedpolypeptides and corresponding nucleic acid molecules from otherspecies.

Definitions

Unless otherwise indicated, the following terms are intended to have themeaning set forth below. Other terms are defined elsewhere throughoutthe specification.

The terms “patient” or “subject” are used interchangeably to refer to ahuman or a non-human animal (e.g., a mammal).

The terms “administration”, “administer” and the like, as they apply to,for example, a subject, cell, tissue, organ, or biological fluid, referto contact of, for example, IL-10 or PEG-IL-10), a nucleic acid (e.g., anucleic acid encoding native human IL-10); a pharmaceutical compositioncomprising the foregoing, or a diagnostic agent to the subject, cell,tissue, organ, or biological fluid. In the context of a cell,administration includes contact (e.g., in vitro or ex vivo) of a reagentto the cell, as well as contact of a reagent to a fluid, where the fluidis in contact with the cell.

The terms “treat”, “treating”, treatment” and the like refer to a courseof action (such as administering IL-10 or a pharmaceutical compositioncomprising IL-10) initiated after a disease, disorder or condition, or asymptom thereof, has been diagnosed, observed, and the like so as toeliminate, reduce, suppress, mitigate, or ameliorate, either temporarilyor permanently, at least one of the underlying causes of a disease,disorder, or condition afflicting a subject, or at least one of thesymptoms associated with a disease, disorder, condition afflicting asubject. Thus, treatment includes inhibiting (e.g., arresting thedevelopment or further development of the disease, disorder or conditionor clinical symptoms association therewith) an active disease. The termsmay also be used in other contexts, such as situations where IL-10 orPEG-IL-10 contacts an IL-10 receptor in, for example, the fluid phase orcolloidal phase.

The term “in need of treatment” as used herein refers to a judgment madeby a physician or other caregiver that a subject requires or willbenefit from treatment. This judgment is made based on a variety offactors that are in the realm of the physician's or caregiver'sexpertise.

The terms “prevent”, “preventing”, “prevention” and the like refer to acourse of action (such as administering IL-10 or a pharmaceuticalcomposition comprising IL-10) initiated in a manner (e.g., prior to theonset of a disease, disorder, condition or symptom thereof) so as toprevent, suppress, inhibit or reduce, either temporarily or permanently,a subject's risk of developing a disease, disorder, condition or thelike (as determined by, for example, the absence of clinical symptoms)or delaying the onset thereof, generally in the context of a subjectpredisposed to having a particular disease, disorder or condition. Incertain instances, the terms also refer to slowing the progression ofthe disease, disorder or condition or inhibiting progression thereof toa harmful or otherwise undesired state.

The term “in need of prevention” as used herein refers to a judgmentmade by a physician or other caregiver that a subject requires or willbenefit from preventative care. This judgment is made based upon avariety of factors that are in the realm of a physician's or caregiver'sexpertise.

The phrase “therapeutically effective amount” refers to theadministration of an agent to a subject, either alone or as part of apharmaceutical composition and either in a single dose or as part of aseries of doses, in an amount capable of having any detectable, positiveeffect on any symptom, aspect, or characteristic of a disease, disorderor condition when administered to the subject. The therapeuticallyeffective amount can be ascertained by measuring relevant physiologicaleffects, and it can be adjusted in connection with the dosing regimenand diagnostic analysis of the subject's condition, and the like. By wayof example, measurement of the amount of inflammatory cytokines producedfollowing administration can be indicative of whether a therapeuticallyeffective amount has been used.

The phrase “in a sufficient amount to effect a change” means that thereis a detectable difference between a level of an indicator measuredbefore (e.g., a baseline level) and after administration of a particulartherapy. Indicators include any objective parameter (e.g., serumconcentration of IL-10) or subjective parameter (e.g., a subject'sfeeling of well-being).

The term “small molecules” refers to chemical compounds having amolecular weight that is less than about 10 kDa, less than about 2 kDa,or less than about 1 kDa. Small molecules include, but are not limitedto, inorganic molecules, organic molecules, organic molecules containingan inorganic component, molecules comprising a radioactive atom, andsynthetic molecules. Therapeutically, a small molecule can be morepermeable to cells, less susceptible to degradation, and less likely toelicit an immune response than large molecules.

The term “ligand” refers to, for example, peptide, polypeptide,membrane-associated or membrane-bound molecule, or complex thereof, thatcan act as an agonist or antagonist of a receptor. “Ligand” encompassesnatural and synthetic ligands, e.g., cytokines, cytokine variants,analogs, muteins, and binding compositions derived from antibodies.“Ligand” also encompasses small molecules, e.g., peptide mimetics ofcytokines and peptide mimetics of antibodies. The term also encompassesan agent that is neither an agonist nor antagonist, but that can bind toa receptor without significantly influencing its biological properties,e.g., signaling or adhesion. Moreover, the term includes amembrane-bound ligand that has been changed, e.g., by chemical orrecombinant methods, to a soluble version of the membrane-bound ligand.A ligand or receptor can be entirely intracellular, that is, it canreside in the cytosol, nucleus, or some other intracellular compartment.The complex of a ligand and receptor is termed a “ligand-receptorcomplex.”

The terms “inhibitors” and “antagonists”, or “activators” and“agonists”, refer to inhibitory or activating molecules, respectively,for example, for the activation of, e.g., a ligand, receptor, cofactor,gene, cell, tissue, or organ. Inhibitors are molecules that decrease,block, prevent, delay activation, inactivate, desensitize, ordown-regulate, e.g., a gene, protein, ligand, receptor, or cell.Activators are molecules that increase, activate, facilitate, enhanceactivation, sensitize, or up-regulate, e.g., a gene, protein, ligand,receptor, or cell. An inhibitor can also be defined as a molecule thatreduces, blocks, or inactivates a constitutive activity. An “agonist” isa molecule that interacts with a target to cause or promote an increasein the activation of the target. An “antagonist” is a molecule thatopposes the action(s) of an agonist. An antagonist prevents, reduces,inhibits, or neutralizes the activity of an agonist, and an antagonistcan also prevent, inhibit, or reduce constitutive activity of a target,e.g., a target receptor, even where there is no identified agonist.

The terms “modulate”, “modulation” and the like refer to the ability ofa molecule (e.g., an activator or an inhibitor) to increase or decreasethe function or activity of an IL-10 agent (or the nucleic acidmolecules encoding them), either directly or indirectly; or to enhancethe ability of a molecule to produce an effect comparable to that of anIL-10 agent. The term “modulator” is meant to refer broadly to moleculesthat can effect the activities described above. By way of example, amodulator of, e.g., a gene, a receptor, a ligand, or a cell, is amolecule that alters an activity of the gene, receptor, ligand, or cell,where activity can be activated, inhibited, or altered in its regulatoryproperties. A modulator can act alone, or it can use a cofactor, e.g., aprotein, metal ion, or small molecule. The term “modulator” includesagents that operate through the same mechanism of action as IL-10 (i.e.,agents that modulate the same signaling pathway as IL-10 in a manneranalogous thereto) and are capable of eliciting a biological responsecomparable to (or greater than) that of IL-10.

Examples of modulators include small molecule compounds and otherbioorganic molecules. Numerous libraries of small molecule compounds(e.g., combinatorial libraries) are commercially available and can serveas a starting point for identifying a modulator. The skilled artisan isable to develop one or more assays (e.g., biochemical or cell-basedassays) in which such compound libraries can be screened in order toidentify one or more compounds having the desired properties;thereafter, the skilled medicinal chemist is able to optimize such oneor more compounds by, for example, synthesizing and evaluating analogsand derivatives thereof. Synthetic and/or molecular modeling studies canalso be utilized in the identification of an Activator.

The “activity” of a molecule can describe or refer to the binding of themolecule to a ligand or to a receptor; to catalytic activity; to theability to stimulate gene expression or cell signaling, differentiation,or maturation; to antigenic activity; to the modulation of activities ofother molecules; and the like. The term can also refer to activity inmodulating or maintaining cell-to-cell interactions (e.g., adhesion), oractivity in maintaining a structure of a cell (e.g., a cell membrane).“Activity” can also mean specific activity, e.g., [catalyticactivity]/[mg protein], or [immunological activity]/[mg protein],concentration in a biological compartment, or the like. The term“proliferative activity” encompasses an activity that promotes, that isnecessary for, or that is specifically associated with, for example,normal cell division, as well as cancer, tumors, dysplasia, celltransformation, metastasis, and angiogenesis.

As used herein, “comparable”, “comparable activity”, “activitycomparable to”, “comparable effect”, “effect comparable to”, and thelike are relative terms that can be viewed quantitatively and/orqualitatively. The meaning of the terms is frequently dependent on thecontext in which they are used. By way of example, two agents that bothactivate a receptor can be viewed as having a comparable effect from aqualitative perspective, but the two agents can be viewed as lacking acomparable effect from a quantitative perspective if one agent is onlyable to achieve 20% of the activity of the other agent as determined inan art-accepted assay (e.g., a dose-response assay) or in anart-accepted animal model. When comparing one result to another result(e.g., one result to a reference standard), “comparable” frequentlymeans that one result deviates from a reference standard by less than35%, by less than 30%, by less than 25%, by less than 20%, by less than15%, by less than 10%, by less than 7%, by less than 5%, by less than4%, by less than 3%, by less than 2%, or by less than 1%. In particularembodiments, one result is comparable to a reference standard if itdeviates by less than 15%, by less than 10%, or by less than 5% from thereference standard. By way of example, but not limitation, the activityor effect can refer to efficacy, stability, solubility, orimmunogenicity.

The term “response,” for example, of a cell, tissue, organ, or organism,encompasses a change in biochemical or physiological behavior, e.g.,concentration, density, adhesion, or migration within a biologicalcompartment, rate of gene expression, or state of differentiation, wherethe change is correlated with activation, stimulation, or treatment, orwith internal mechanisms such as genetic programming. In certaincontexts, the terms “activation”, “stimulation”, and the like refer tocell activation as regulated by internal mechanisms, as well as byexternal or environmental factors; whereas the terms “inhibition”,“down-regulation” and the like refer to the opposite effects.

The terms “polypeptide,” “peptide,” and “protein”, used interchangeablyherein, refer to a polymeric form of amino acids of any length, whichcan include genetically coded and non-genetically coded amino acids,chemically or biochemically modified or derivatized amino acids, andpolypeptides having modified polypeptide backbones. The terms includefusion proteins, including, but not limited to, fusion proteins with aheterologous amino acid sequence; fusion proteins with heterologous andhomologous leader sequences; fusion proteins with or without N-terminusmethionine residues; fusion proteins with immunologically taggedproteins; and the like.

It will be appreciated that throughout this disclosure reference is madeto amino acids according to the single letter or three letter codes. Forthe reader's convenience, the single and three letter amino acid codesare provided below:

G Glycine Gly P Proline Pro A Alanine Ala V Valine Val L Leucine Leu IIsoleucine Ile M Methionine Met C Cysteine Cys F Phenylalanine Phe YTyrosine Tyr W Tryptophan Trp H Histidine His K Lysine Lys R ArginineArg Q Glutamine Gln N Asparagine Asn E Glutamic Acid Glu D Aspartic AcidAsp S Serine Ser T Threonine Thr

As used herein, the term “variant” encompasses naturally-occurringvariants and non-naturally-occurring variants. Naturally-occurringvariants include homologs (polypeptides and nucleic acids that differ inamino acid or nucleotide sequence, respectively, from one species toanother), and allelic variants (polypeptides and nucleic acids thatdiffer in amino acid or nucleotide sequence, respectively, from oneindividual to another within a species). Non-naturally-occurringvariants include polypeptides and nucleic acids that comprise a changein amino acid or nucleotide sequence, respectively, where the change insequence is artificially introduced (e.g., muteins); for example, thechange is generated in the laboratory by human intervention (“hand ofman”). Thus, herein a “mutein” refers broadly to mutated recombinantproteins that usually carry single or multiple amino acid substitutionsand are frequently derived from cloned genes that have been subjected tosite-directed or random mutagenesis, or from completely synthetic genes.

The terms “DNA”, “nucleic acid”, “nucleic acid molecule”,“polynucleotide” and the like are used interchangeably herein to referto a polymeric form of nucleotides of any length, eitherdeoxyribonucleotides or ribonucleotides, or analogs thereof.Non-limiting examples of polynucleotides include linear and circularnucleic acids, messenger RNA (mRNA), complementary DNA (cDNA),recombinant polynucleotides, vectors, probes, primers and the like.

As used herein in the context of the structure of a polypeptide,“N-terminus” (or “amino terminus”) and “C-terminus” (or “carboxylterminus”) refer to the extreme amino and carboxyl ends of thepolypeptide, respectively, while the terms “N-terminal” and “C-terminal”refer to relative positions in the amino acid sequence of thepolypeptide toward the N-terminus and the C-terminus, respectively, andcan include the residues at the N-terminus and C-terminus, respectively.“Immediately N-terminal” or “immediately C-terminal” refers to aposition of a first amino acid residue relative to a second amino acidresidue where the first and second amino acid residues are covalentlybound to provide a contiguous amino acid sequence.

“Derived from”, in the context of an amino acid sequence orpolynucleotide sequence (e.g., an amino acid sequence “derived from” anIL-10 polypeptide), is meant to indicate that the polypeptide or nucleicacid has a sequence that is based on that of a reference polypeptide ornucleic acid (e.g., a naturally occurring IL-10 polypeptide or anIL-10-encoding nucleic acid), and is not meant to be limiting as to thesource or method in which the protein or nucleic acid is made. By way ofexample, the term “derived from” includes homologs or variants ofreference amino acid or DNA sequences.

In the context of a polypeptide, the term “isolated” refers to apolypeptide of interest that, if naturally occurring, is in anenvironment different from that in which it can naturally occur.“Isolated” is meant to include polypeptides that are within samples thatare substantially enriched for the polypeptide of interest and/or inwhich the polypeptide of interest is partially or substantiallypurified. Where the polypeptide is not naturally occurring, “isolated”indicates that the polypeptide has been separated from an environment inwhich it was made by either synthetic or recombinant means.

“Enriched” means that a sample is non-naturally manipulated (e.g., by ascientist) so that a polypeptide of interest is present in a) a greaterconcentration (e.g., at least 3-fold greater, at least 4-fold greater,at least 8-fold greater, at least 64-fold greater, or more) than theconcentration of the polypeptide in the starting sample, such as abiological sample (e.g., a sample in which the polypeptide naturallyoccurs or in which it is present after administration), or b) aconcentration greater than the environment in which the polypeptide wasmade (e.g., as in a bacterial cell).

“Substantially pure” indicates that a component (e.g., a polypeptide)makes up greater than about 50% of the total content of the composition,and typically greater than about 60% of the total polypeptide content.More typically, “substantially pure” refers to compositions in which atleast 75%, at least 85%, at least 90% or more of the total compositionis the component of interest. In some cases, the polypeptide will makeup greater than about 90%, or greater than about 95% of the totalcontent of the composition.

The terms “specifically binds” or “selectively binds”, when referring toa ligand/receptor, antibody/antigen, or other binding pair, indicates abinding reaction which is determinative of the presence of the proteinin a heterogeneous population of proteins and other biologics. Thus,under designated conditions, a specified ligand binds to a particularreceptor and does not bind in a significant amount to other proteinspresent in the sample. The antibody, or binding composition derived fromthe antigen-binding site of an antibody, of the contemplated methodbinds to its antigen, or a variant or mutein thereof, with an affinitythat is at least two-fold greater, at least ten times greater, at least20-times greater, or at least 100-times greater than the affinity withany other antibody, or binding composition derived therefrom. In aparticular embodiment, the antibody will have an affinity that isgreater than about 10⁹ liters/mol, as determined by, e.g., Scatchardanalysis (Munsen, et al. 1980 Analyt. Biochem. 107:220-239).

IL-10 and PEG-IL-10

The anti-inflammatory cytokine IL-10, also known as human cytokinesynthesis inhibitory factor (CSIF), is classified as a type(class)-2cytokine, a set of cytokines that includes IL-19, IL-20, IL-22, IL-24(Mda-7), and IL-26, interferons (IFN-α, -β, -γ, -δ, -ε, -κ, -Ω, and -τ)and interferon-like molecules (limitin, IL-28A, IL-28B, and IL-29).

IL-10 is a cytokine with pleiotropic effects in immunoregulation andinflammation. It is produced by mast cells, counteracting theinflammatory effect that these cells have at the site of an allergicreaction. While it is capable of inhibiting the synthesis ofpro-inflammatory cytokines such as IFN-γ, IL-2, IL-3, TNFα and GM-CSF,IL-10 is also stimulatory towards certain T cells and mast cells andstimulates B-cell maturation, proliferation and antibody production.IL-10 can block NF-κB activity and is involved in the regulation of theJAK-STAT signaling pathway. It also induces the cytotoxic activity ofCD8+ T-cells and the antibody production of B-cells, and it suppressesmacrophage activity and tumor-promoting inflammation. The regulation ofCD8+ T-cells is dose-dependent, wherein higher doses induce strongercytotoxic responses.

Human IL-10 is a homodimer with a molecular mass of 37 kDa, wherein each18.5 kDa monomer comprises 178 amino acids, the first 18 of whichcomprise a signal peptide, and two cysteine residues that form twointramolecular disulfide bonds. The IL-10 dimer becomes biologicallyinactive upon disruption of the non-covalent interactions between thetwo monomer subunits.

The present disclosure contemplates human IL-10 (NP_000563) and murineIL-10 (NP_034678), which exhibit 80% homology, and use thereof. Inaddition, the scope of the present disclosure includes IL-10 orthologs,and modified forms thereof, from other mammalian species, including rat(accession NP_036986.2; GI 148747382); cow (accession NP_776513.1; GI41386772); sheep (accession NP_001009327.1; GI 57164347); dog (accessionABY86619.1; GI 166244598); and rabbit (accession AAC23839.1; GI3242896).

As alluded to above, the terms “IL-10”, “IL-10 polypeptide(s), “IL-10molecule(s)”, “IL-10 agent(s)” and the like are intended to be broadlyconstrued and include, for example, human and non-human IL-10-relatedpolypeptides, including homologs, variants (including muteins), andfragments thereof, as well as IL-10 polypeptides having, for example, aleader sequence (e.g., the signal peptide), and modified versions of theforegoing. In further particular embodiments, IL-10, IL-10polypeptide(s), and IL-10 agent(s) are agonists.

The IL-10 receptor, a type II cytokine receptor, consists of alpha andbeta subunits, which are also referred to as R1 and R2, respectively.Receptor activation requires binding to both alpha and beta. Onehomodimer of an IL-10 polypeptide binds to alpha and the other homodimerof the same IL-10 polypeptide binds to beta.

The utility of recombinant human IL-10 is frequently limited by itsrelatively short serum half-life, which can be due to, for example,renal clearance, proteolytic degradation and monomerization in the bloodstream. As a result, various approaches have been explored to improvethe pharmacokinetic profile of IL-10 without disrupting its dimericstructure and thus adversely affecting its activity. Pegylation of IL-10results in improvement of certain pharmacokinetic parameters (e.g.,serum half-life) and/or enhancement of activity.

As used herein, the terms “pegylated IL-10” and “PEG-IL-10” refer to anIL-10 molecule having one or more polyethylene glycol moleculescovalently attached to at least one amino acid residue of the IL-10protein, generally via a linker, such that the attachment is stable. Theterms “monopegylated IL-10” and “mono-PEG-IL-10” indicate that onepolyethylene glycol molecule is covalently attached to a single aminoacid residue on one subunit of the IL-10 dimer, generally via a linker.As used herein, the terms “dipegylated IL-10” and “di-PEG-IL-10”indicate that at least one polyethylene glycol molecule is attached to asingle residue on each subunit of the IL-10 dimer, generally via alinker.

In certain embodiments, the PEG-IL-10 used in the present disclosure isa mono-PEG-IL-10 in which one to nine PEG molecules are covalentlyattached via a linker to the alpha amino group of the amino acid residueat the N-terminus of one subunit of the IL-10 dimer. Monopegylation onone IL-10 subunit generally results in a non-homogeneous mixture ofnon-pegylated, monopegylated and dipegylated IL-10 due to subunitshuffling. Moreover, allowing a pegylation reaction to proceed tocompletion will generally result in non-specific and multi-pegylatedIL-10, thus reducing its bioactivity. Thus, particular embodiments ofthe present disclosure comprise the administration of a mixture of mono-and di-pegylated IL-10 produced by the methods described herein.

In particular embodiments, the average molecular weight of the PEGmoiety is between about 5 kDa and about 50 kDa. Although the method orsite of PEG attachment to IL-10 is not critical, in certain embodimentsthe pegylation does not alter, or only minimally alters, the activity ofthe IL-10 agent. In certain embodiments, the increase in half-life isgreater than any decrease in biological activity. The biologicalactivity of PEG-IL-10 is typically measured by assessing the levels ofinflammatory cytokines (e.g., TNF-α or IFN-γ) in the serum of subjectschallenged with a bacterial antigen (lipopolysaccharide (LPS)) andtreated with PEG-IL-10, as described in U.S. Pat. No. 7,052,686.

IL-10 variants can be prepared with various objectives in mind,including increasing serum half-life, reducing an immune responseagainst the IL-10, facilitating purification or preparation, decreasingconversion of IL-10 into its monomeric subunits, improving therapeuticefficacy, and lessening the severity or occurrence of side effectsduring therapeutic use. The amino acid sequence variants are usuallypredetermined variants not found in nature, although some can bepost-translational variants, e.g., glycosylated variants. Any variant ofIL-10 can be used provided it retains a suitable level of IL-10activity.

The phrase “conservative amino acid substitution” refers tosubstitutions that preserve the activity of the protein by replacing anamino acid(s) in the protein with an amino acid with a side chain ofsimilar acidity, basicity, charge, polarity, or size of the side chain.Conservative amino acid substitutions generally entail substitution ofamino acid residues within the following groups: 1) L, I, M, V, F; 2) R,K; 3) F, Y, H, W, R; 4) G, A, T, S; 5) Q, N; and 6) D, E. Guidance forsubstitutions, insertions, or deletions can be based on alignments ofamino acid sequences of different variant proteins or proteins fromdifferent species. Thus, in addition to any naturally-occurring IL-10polypeptide, the present disclosure contemplates having 1, 2, 3, 4, 5,6, 7, 8, 9, or 10 usually no more than 20, 10, or 5 amino acidsubstitutions, where the substitution is usually a conservative aminoacid substitution.

The present disclosure also contemplates active fragments (e.g.,subsequences) of mature IL-10 containing contiguous amino acid residuesderived from the mature IL-10. The length of contiguous amino acidresidues of a peptide or a polypeptide subsequence varies depending onthe specific naturally-occurring amino acid sequence from which thesubsequence is derived. In general, peptides and polypeptides can befrom about 20 amino acids to about 40 amino acids, from about 40 aminoacids to about 60 amino acids, from about 60 amino acids to about 80amino acids, from about 80 amino acids to about 100 amino acids, fromabout 100 amino acids to about 120 amino acids, from about 120 aminoacids to about 140 amino acids, from about 140 amino acids to about 150amino acids, from about 150 amino acids to about 155 amino acids, fromabout 155 amino acids up to the full-length peptide or polypeptide.

Additionally, IL-10 polypeptides can have a defined sequence identitycompared to a reference sequence over a defined length of contiguousamino acids (e.g., a “comparison window”). Methods of alignment ofsequences for comparison are well-known in the art. Optimal alignment ofsequences for comparison can be conducted, e.g., by the local homologyalgorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by thehomology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443(1970), by the search for similarity method of Pearson & Lipman, Proc.Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations ofthese algorithms (GAP, BESTFIT, FASTA, and TFASTA in the WisconsinGenetics Software Package, Madison, Wis.), or by manual alignment andvisual inspection (see, e.g., Current Protocols in Molecular Biology(Ausubel et al., eds. 1995 supplement)).

As an example, a suitable IL-10 polypeptide can comprise an amino acidsequence having at least about 75%, at least about 80%, at least about85%, at least about 90%, at least about 95%, at least about 98%, or atleast about 99%, amino acid sequence identity to a contiguous stretch offrom about 20 amino acids to about 40 amino acids, from about 40 aminoacids to about 60 amino acids, from about 60 amino acids to about 80amino acids, from about 80 amino acids to about 100 amino acids, fromabout 100 amino acids to about 120 amino acids, from about 120 aminoacids to about 140 amino acids, from about 140 amino acids to about 150amino acids, from about 150 amino acids to about 155 amino acids, fromabout 155 amino acids up to the full-length peptide or polypeptide.

As discussed further below, the IL-10 polypeptides can be isolated froma natural source (e.g., an environment other than itsnaturally-occurring environment) and can also be recombinantly made(e.g., in a genetically modified host cell such as bacteria, yeast,Pichia, insect cells, and the like), where the genetically modified hostcell is modified with a nucleic acid comprising a nucleotide sequenceencoding the polypeptide. The IL-10 polypeptides can also besynthetically produced (e.g., by cell-free chemical synthesis).

Nucleic acid molecules encoding the IL-10 agents are contemplated by thepresent disclosure, including their naturally-occurring andnon-naturally occurring isoforms, allelic variants and splice variants.The present disclosure also encompasses nucleic acid sequences that varyin one or more bases from a naturally-occurring DNA sequence but stilltranslate into an amino acid sequence that corresponds to an IL-10polypeptide due to degeneracy of the genetic code.

Chimeric Antigen Receptor T Cells

Chimeric antigen receptor T cells (CARs; also known as artificial T cellreceptors, chimeric T cell receptors, and chimeric immunoreceptors)represent an emerging therapy for cancer (e.g., treatment of B and Tcell lymphomas) and other malignancies. CAR-T T cells generally comprisepatient-derived memory CD8+ T cells modified to express a recombinant Tcell receptor specific for a known antigen present on, for example, atumor of interest. Other types of T cells contemplated herein includenaïve T cells, central memory T cells, effector memory T cells orcombination thereof. While the present disclosure is generally describedin the context of using CAR-T cell therapy for the treatment of cancer,it is to be understood that such therapy is not so limited.

CAR-T T cell therapy comprises use of adoptive cell transfer (ACT). ACT,which utilizes a patient's own cultured T cells, has shown promise as apatient-specific cancer therapy (Snook and Waldman (2013) Discov Med15(81):120-25). The use of genetic engineering approaches to insertantigen-targeted receptors of defined specificity into T cells hasgreatly extended the potential capabilities of ACT. In most instances,these engineered chimeric antigen receptors are used to graft thespecificity of a monoclonal antibody onto a T cell.

The initiation of CAR-T cell therapy comprises the removal of T cellsfrom a patient. The T cells are then genetically engineered to expressCARs directed towards antigens specific for a known cancer (e.g., atumor). Following amplification ex vivo to a sufficient number, theautologous cells are infused back into the patient, resulting in theantigen-specific destruction of the cancer.

CARs are a type of antigen-targeted receptor composed of intracellularT-cell signaling domains generally fused to extracellular tumor-bindingmoieties, most commonly single-chain variable fragments (scFvs) frommonoclonal antibodies. CARs directly recognize cell surface antigens,independent of MHC-mediated presentation, permitting the use of a singlereceptor construct specific for any given antigen in all patients.

Chimeric antigen receptors generally comprise several primarycomponents, some of which are described hereafter.

As used herein, the phrase “antigen-specific targeting region” (ASTR)refers to the region that directs the CAR to specific antigens. Thetargeting regions on the CAR are extracellular. In particularembodiments of the present disclosure, the CARs comprise at least twotargeting regions which target at least two different antigens. Infurther particular embodiments, the CARs comprise three or moretargeting regions which target at least three or more differentantigens. In some embodiments, the antigen-specific targeting regionscomprise an antibody or a functional equivalent thereof or a fragmentthereof or a derivative thereof, and each of the targeting regionstargets a different antigen. The targeting regions may comprisefull-length heavy chain, Fab fragments, single chain Fv (scFv)fragments, divalent single chain antibodies or diabodies, each of whichare specific to the target antigen. In certain aspects of the presentdisclosure, the targeting regions may comprise linked cytokines, ligandbinding domains from naturally occurring receptors, solubleprotein-peptide ligands for a receptor, peptides, affibodies andvaccines to prompt an immune response. The skilled artisan is aware ofother molecules that can be used as an antigen-specific targetingregion.

As used herein, the term “extracellular spacer domain” (ESD) refer tothe hydrophilic region between the antigen-specific targeting region andthe transmembrane domain. The present disclosure contemplatesembodiments wherein the CARs comprise an ESD, examples of which includeFc Ab fragments, or fragments or derivatives thereof; hinge regions ofantibodies or fragments or derivatives thereof; CH2 or CH3 regions ofantibodies; artificial spacer sequences, including Gly3 or CH1 and CH3domains of IgGs (such as human IgG4); or combinations of the foregoing.One of ordinary skill in the art is aware of other ESDs, which arecontemplated herein.

As used herein, the term “transmembrane domain” (TMD) refers to theregion of the CAR which traverses the plasma membrane. In someembodiments, the transmembrane region is a transmembrane protein (e.g.,a Type I transmembrane protein), an artificial hydrophobic sequence, ora combination thereof. The skilled artisan is aware of othertransmembrane domains which may be used in conjunction with theteachings of the present disclosure.

As used herein, the terms “intracellular signaling domain” (ISD) and“cytoplasmic domain” refer to the portion of the CAR which transducesthe effector function signal and directs the cell to perform itsspecialized function. Examples of ISDs include the zeta chain of theT-cell receptor complex or any of its homologs (e.g., eta. chain, FcεR1γand β chains, MB1 (Igα) chain, B29 (Igβ) chain, etc.), human CD3 zetachain, CD3 polypeptides (δ, Δ and ε), syk family tyrosine kinases (Syk,ZAP 70, etc.), src family tyrosine kinases (Lck, Fyn, Lyn, etc.) andother molecules involved in T-cell transduction, such as CD2, CD5 andCD28. The skilled artisan is aware of other ISDs that may be used inconjunction with the teachings of the present disclosure.

The term “co-stimulatory domain” (CSD) refers to the portion of the CARwhich enhances the proliferation, survival or development of memorycells. As indicated elsewhere herein, the CARs of the present disclosuremay comprise one or more co-stimulatory domains. In some embodiments ofthe present disclosure, the CSD comprises one or more of members of theTNFR superfamily, CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2,CD5, ICAM-1, LFA-1 (CD11a/CD18), Lck, TNFR-I, TNFR-II, Fas, CD30, CD40or combinations thereof. The ordinarily skilled artisan is aware ofother co-stimulatory domains that may be used in conjunction with theteachings of the present disclosure.

As used in conjunction with the CAR-T T cell technology describedherein, the terms “linker”, “linker domain” and “linker region” refer toan oligo- or polypeptide region from about 1 to 100 amino acids inlength, which links together any of the domains/regions of the CAR ofthe disclosure. Linkers may be composed of flexible residues likeglycine and serine so that the adjacent protein domains are free to moverelative to one another. Certain embodiments comprise the use of linkersof longer length when it is desirable to ensure that two adjacentdomains do not sterically interfere with each another. In someembodiments, the linkers are non-cleavable, while in others they arecleavable (e.g., 2A linkers (for example T2A)), 2A-like linkers orfunctional equivalents thereof, and combinations of the foregoing.Embodiments of the present disclosure are contemplated wherein thelinkers include the picornaviral 2A-like linker, CHYSEL sequences ofporcine teschovirus (P2A), Thosea asigna virus (T2A), or combinations,variants and functional equivalents thereof. In still furtherembodiments, the linker sequences compriseAsp-Val/Ile-Glu-X-Asn-Pro-Gly^((2A))-pro^((2B)) motif, which results incleavage between the 2A glycine and the 2B proline. Other linkers willbe readily apparent to the skilled artisan and are contemplated for usewith the teachings of the present disclosure.

There has been a relatively rapid progression of CAR-T T cell therapy(see generally, US Patent Appln Publn No 20150038684). First generationCARs were directed to fusion of antigen-recognition domains to the CD3ζactivation chain of the T-cell receptor (TCR) complex. While these firstgeneration CARs induced T-cell effector function in vitro, in vivoefficacy was largely limited by their poor antitumor efficacy. Evolutionof CAR technology resulted in second generation CARs, which include theCD3ζ activation chain in tandem with one CSD, examples of which includeintracellular domains from CD28 or a variety of TNF receptor familymolecules such as 4-1BB (CD137) and OX40 (CD134). Third generation CARshave been developed that include two costimulatory signals in additionto the CD3ζ activation chain, the CSDs most commonly being from CD28 and4-1BB. Second and third generation CARs dramatically improved antitumorefficacy. However, it is not entirely clear if specific combinations ofcostimulatory molecules are advantageous over others. Moreover, theincreased potency of second and third generation CARs, coupled with thelack of truly tumor-specific antigen-targets, has also increased therisk of severe toxicities. (See, e.g., Carpenito et al. (2009) Proc NatlAcad Sci USA 106(9):3360-65; Grupp et al. (2013) N Engl J Med368(16):1509-18).

Activation-Induced Cell Death

The infusion of genetically-modified T cells directed to specific targetantigens has several potential benefits, including long-term diseasecontrol, rapid onset of action similar to that of cytotoxic chemotherapyor with targeted therapies, and circumvention of both immune toleranceof the T cell repertoire and MHC restriction. However, treatment ofcertain cancers (e.g., non-B cell malignancies) with CAR-T cell therapyhas, in part, been limited by both the induction of antigen-specifictoxicities targeting normal tissues expressing the target-antigen, andthe extreme potency of CAR-T cell treatments, sometimes resulting inlife-threatening cytokine-release syndromes (Magee (November 2014)Discov Med 18(100):265-71). In particular, it has been observed thathigh affinity T cell receptor interactions with significant antigenburden can lead to activation-induced cell death (Song et al. (2012)Blood 119(3):696-706; Hombach et al (2013) Mol Ther 21(12):2268-77).

Activation-induced cell death (AICD), programmed cell death that resultsfrom the interaction of Fas receptors (e.g., Fas, CD95) with Fas ligands(e.g., FasL, CD95 ligand), helps to maintain peripheral immunetolerance. The AICD effector cell expresses FasL, and apoptosis isinduced in the cell expressing the Fas receptor. Activation-induced celldeath is a negative regulator of activated T lymphocytes resulting fromrepeated stimulation of their T cell receptors. Alteration of thisprocess may lead to autoimmune diseases (Zhang J, et al. (2004) Cell MolImmunol. 1(3):186-92).

Mechanistically, the binding of a Fas ligand to a Fas receptor triggerstrimerization of the Fas receptor, whose cytoplasmic domain is then ableto bind the death domain of the adaptor protein FADD (Fas-associatedprotein with death domain). Procaspase 8 binds to FADD's death effectordomain and proteolytically self-activates caspase 8; Fas, FADD, andprocaspase 8 together form a death-inducing signaling complex. Activatedcaspase 8 is released into the cytosol, where it activates the caspasecascade that initiates apoptosis (Nagata S. (1997) Cell. 88(3):355-65s.

The balance of activation-induced proliferation and death of effectercells is a key point in the homeostatic expansion of T cells. Whileresting T cells are susceptible to apoptosis, stimulation of T cellsthrough TCR/CD3 in the presence of cytokines (e.g., IL-2, IL-4, IL-7 andIL-12) results in clonal expansion. Interestingly, the roles of thesemolecules in the homeostasis of T cells are sometimes paradoxical. Byway of example, IL-2 is necessary for proliferation and survival of CD4+T cells, but it is also a prerequisite for activation-induced celldeath. Moreover, IL-18 has been shown to promote expansion and survivalof activated CD8+ T cells. IL-18 may influence immune/inflammatoryresponses by regulating the size of the CD8+ T cell population withspecific functions following exposure to stimuli. Regulation ofproliferation and activation-induced cell death of activated T cells isclosely associated with immune/inflammatory responses (Li, W., et al.(July 2007) J Leukocyte Bio 82(1):142-51).

Effect of IL-10 on CAR-T T Cell Therapy

The characteristics of IL-10 agents (e.g., PEG-IL-10) are describedelsewhere herein. As an anti-inflammatory and immunosuppressivemolecule, IL-10 inhibits antigen presentation, CD4+ T cell function,CD8+ T cell pathogen-specific function (Biswas et al. (2007) J Immunol179(7):4520-28), viral epitope-specific CD8+ T cell IFNγ responses (Liuet al. (2003) J Immunol 171(9):4765-72), and anti-LCMV (LymphocyticChoriomeningitis Virus) CD8+ T cell responses (Brooks et al. (2008) PNASUSA 105(51):20428-433).

While IL-10 has been discussed in the context of enhancement ofactivation-induced cell death (Georgescu et al. (1997) J Clin Invest100(10):2622-33), in vitro and in vivo data presented herein indicatethat an IL-10 agent (e.g., PEG-IL-10) may be combined with CAR-T T celltherapy to prevent or limit activation-induced cell death whileenhancing CD8+ T cell function and survival.

By way of example, the findings presented in Example 1 of theExperimental section suggest that PEG-IL-10 administration mediated CD8+T cell immune activation. As described in Example 1, the number of PD-1-and LAG3-expressing CD8+ T cells was compared in oncology patientsbefore and after treatment with PEG-rHuIL-10 (see Example 1). Both PD-1and LAG3 are markers of CD8+ T cell activation and cytotoxic function.The number of peripheral CD8+ T cells expressing PD-1 increased by˜2-fold, and the number of peripheral CD8+ T cells expressing LAG3increased by ˜4-fold. Taken as a whole, these data indicate thatPEG-IL-10 administration mediated CD8+ T cell immune activation.

Administration of PEG-IL-10 was also observed to enhance the function ofactivated memory CD8+ T cells (see Example 2). Memory T cells (alsoreferred to as antigen-experienced T cells) are a subset of Tlymphocytes (e.g., helper T cells (CD4+) and cytotoxic T cells (CD8+))that have previously encountered and responded to their cognate antigenduring prior infection, exposure to cancer, or previous vaccination. Incontrast, naïve T cells have not encountered their cognate antigenwithin the periphery; they are commonly characterized by the absence ofthe activation markers CD25, CD44 or CD69, and the absence of memoryCD45RO isoform. Memory T cells, which are generally CD45RO+, are able toreproduce and mount a faster and stronger immune response than naïve Tcells.

Because CAR-T T cells are derived from memory CD8+ T cells, the effectof PEG-IL-10 on memory CD8+ T cells was assessed in vitro. The datapresented in Example 2 are consistent with the effect of PEG-IL-10 toenhance the function of activated memory CD8+ T cells.

Methods and Models

The present disclosure contemplates various methods and models foridentifying candidate subject populations (or individual subjects)having undergone or suspected of having undergone activation-inducedcell death as a result of CAR-T cell therapy that can be responsive tothe therapies described herein. Such therapies include monotherapy withan IL-10 agent (e.g., PEG-IL-10) and combination therapy with an IL-10agent and one or more distinct agents that have been shown to exhibitbeneficial activity in preventing or limiting activation-induced celldeath. In some embodiments, the methods and models allow a determinationof whether administration of and IL-10 agent achieves the desired levelof a reduction in activation-induced cell death or whether a combinationof an IL-10 agent and another agent is more beneficial. In otherembodiments, the methods and models allow a determination of whetheradministration of the combination results in fewer undesirable effects.

Certain embodiments of the present disclosure comprise the use of invitro, ex vivo and in vivo methods and/or models. The subject population(or individual subject) is a non-human animal (e.g., rodent) or human incertain embodiments of the present disclosure.

By way of example, but not limitation, one aspect of the presentdisclosure contemplates a method for determining whether a test subjecthaving undergone or suspected of having undergone activation-inducedcell death is a candidate for treatment with an of IL-10 agent (e.g.,PEG-IL-10), the method comprising a) providing a test subject having anindicia of activation-induced cell death, b) administering the IL-10agent to the test subject in an amount sufficient to achieve a desiredresponse in a reference population, and c) determining whether the testsubject exhibits the desired response; wherein the determination of thedesired response indicates that the test subject is a candidate fortreatment. The skilled artisan is able to modify such methods for usewith combination therapy. The desired response can be any result deemedfavorable under the circumstances.

As indicated above, the present disclosure also contemplates variousmodels. Any model can be used that provides reliable, reproducibleresults. The skilled artisan is familiar with models that can be used inconjunction with the subject matter of the present disclosure; in oneembodiment, the IL-10 agent (e.g., PEG-IL-10) is evaluated in a modelcomprising a non-human subject (e.g., a mouse). Particular embodimentsof the present disclosure contemplate a model for determining whether anIL-10 agent, in combination with or without another agent, is acandidate for preventing or reducing activation-induced cell death.

Further embodiments of the present disclosure comprise a method or modelfor determining the optimum amount of an IL-10 agent, in combinationwith or without another agent. An optimum amount can be, for example, anamount that achieves an optimal effect in a subject or subjectpopulation. By manipulating the amounts of the agent(s), a clinician isable to determine the optimal dosing regimen for preventing or reducingactivation-induced cell death.

Biomarkers

The present disclosure also contemplates the use of biomarkers inconjunction with the methods and models described herein. The term“biomarker(s)” refers to a characteristic that is objectively measuredand evaluated as an indicator of normal biological processes, pathogenicprocesses, or pharmacologic responses to a therapeutic intervention. Theindicator may be any substance, structure, or process that can bemeasured in the body or its products and influences or predicts theincidence of outcome or disease.

In some embodiments of the present disclosure, a biomarker(s) is used topredict a clinical response(s) to therapy with an IL-10 agent (e.g.,PEG-IL-10). In some instances, a pre-treatment biomarker can be used insuch therapy wherein the biomarker has been validated to the point atwhich it could be applied as part of standard-of-care therapeuticdecision-making.

Serum Concentrations

The blood plasma levels of IL-10 in the methods described herein can becharacterized in several manners, including: (1) a mean IL-10 serumtrough concentration above some specified level or in a range of levels;(2) a mean IL-10 serum trough concentration above some specified levelfor some amount of time; (3) a steady state IL-10 serum concentrationlevel above or below some specified level or in a range of levels; or(4) a C_(max) of the concentration profile above or below some specifiedlevel or in some range of levels. As set forth herein, mean serum troughIL-10 concentrations have been found to be of particular import forefficacy in certain indications.

In some embodiments of the present disclosure, blood plasma and/or serumlevel concentration profiles that can be produced include: a mean IL-10plasma and/or serum trough concentration of greater than about 1.0pg/mL, greater than about 10.0 pg/mL, greater than about 20.0 pg/mL,greater than about 30 pg/mL, greater than about 40 pg/mL, greater thanabout 50.0 pg/mL, greater than about 60.0 pg/mL, greater than about 70.0pg/mL, greater than about 80.0 pg/mL, greater than about 90 pg/mL,greater than about 0.1 ng/mL, greater than about 0.2 ng/mL, greater thanabout 0.3 ng/mL, greater than about 0.4 ng/mL, greater than about 0.5ng/mL, greater than about 0.6 ng/mL, greater than about 0.7 ng/mL,greater than about 0.8 ng/mL, greater than about 0.9 ng/mL, greater thanabout 1.0 ng/mL, greater than about 1.5 ng/mL, greater than about 2.0ng/mL, greater than about 2.5 ng/mL, greater than about 3.0 ng/mL,greater than about 3.5 ng/mL, greater than about 4.0 ng/mL, greater thanabout 4.5 ng/mL, greater than about 5.0 ng/mL, greater than about 5.5ng/mL, greater than about 6.0 ng/mL, greater than about 6.5 ng/mL,greater than about 7.0 ng/mL, greater than about 7.5 ng/mL, greater thanabout 8.0 ng/mL, greater than about 8.5 ng/mL, greater than about 9.0ng/mL, greater than about 9.5 ng/mL, or greater than about 10.0 ng/mL.

In particular embodiments of the present disclosure, a mean IL-10 serumtrough concentration is in the range of from 1.0 pg/mL to 10 ng/mL. Insome embodiments, the mean IL-10 serum trough concentration is in therange of from 1.0 pg/mL to 100 pg/mL. In other embodiments, the meanIL-10 serum trough concentration is in the range of from 0.1 ng/mL to1.0 ng/mL. In still other embodiments, the mean IL-10 serum troughconcentration is in the range of from 1.0 ng/mL to 10 ng/mL. It is to beunderstood that the present disclosure contemplates ranges incorporatingany concentrations encompassed by those set forth herein even if suchranges are not explicitly recited. By way of example, the mean serumIL-10 concentration in an embodiment can be in the range of from 0.5ng/mL to 5 ng/mL. By way of further examples, particular embodiments ofthe present disclosure comprise a mean IL-10 serum trough concentrationin a range of from about 0.5 ng/mL to about 10.5 ng/mL, from about 1.0ng/mL to about 10.0 ng/mL, from about 1.0 ng/mL to about 9.0 ng/mL, fromabout 1.0 ng/mL to about 8.0 ng/mL, from about 1.0 ng/mL to about 7.0ng/mL, from about 1.5 ng/mL to about 10.0 ng/mL, from about 1.5 ng/mL toabout 9.0 ng/mL, from about 1.5 ng/mL to about 8.0 ng/mL, from about 1.5ng/mL to about 7.0 ng/mL, from about 2.0 ng/mL to about 10.0 ng/mL, fromabout 2.0 ng/mL to about 9.0 ng/mL, from about 2.0 ng/mL to about 8.0ng/mL, and from about 2.0 ng/mL to about 7.0 ng/mL.

In particular embodiments, a mean IL-10 serum trough concentration of1-2 ng/mL is maintained over the duration of treatment. The presentdisclosure also contemplates embodiments wherein the mean IL-10 serumpeak concentration is less than or equal to about 10.0 ng/mL over theduration of treatment. Further embodiments contemplate a mean IL-10serum trough concentration greater than or equal to about 1.0 pg/mL. Theoptimal mean serum concentration is generally that at which the desiredtherapeutic effect is achieved without introducing undesired adverseeffects.

Certain embodiments of the present disclosure provide a method formonitoring a subject receiving IL-10 therapy to predict, and thuspotentially avoid, adverse effects, the method comprising: (1) measuringthe subject's peak concentration of IL-10; (2) measuring the subject'strough concentration of IL-10; (3) calculating a peak-troughfluctuation; and, (4) using the calculated peak-trough fluctuation topredict potential adverse effects in the subject. In particular subjectpopulations, a smaller peak-trough fluctuation indicates a lowerprobability that the subject will experience IL-10-related adverseeffects. In addition, in some embodiments particular peak-troughfluctuations are determined for the treatment of particular diseases,disorders and conditions using particular dosing parameters, and thosefluctuations are used as reference standards.

For the majority of drugs, plasma drug concentrations decline in amulti-exponential fashion. Immediately after intravenous administration,the drug rapidly distributes throughout an initial space (minimallydefined as the plasma volume), and then a slower, equilibrativedistribution to extravascular spaces (e.g., certain tissues) occurs.Intravenous IL-10 administration is associated with such atwo-compartment kinetic model (see Rachmawati, H. et al. (2004) Pharm.Res. 21(11):2072-78). The pharmacokinetics of subcutaneous recombinanthIL-10 has also been studied (Radwanski, E. et al. (1998) Pharm. Res.15(12):1895-1901). Thus, volume-of-distribution considerations arepertinent when assessing appropriate IL-10 dosing-related parameters.Moreover, efforts to target IL-10 agents to specific cell types havebeen explored (see, e.g., Rachmawati, H. (May 2007) Drug Met. Dist.35(5):814-21), and the leveraging of IL-10 pharmacokinetic and dosingprinciples can prove invaluable to the success of such efforts.

The present disclosure contemplates administration of any dose anddosing regimen that results in maintenance of any of the IL-10 serumtrough concentrations set forth above. By way of example, but notlimitation, when the subject is a human, non-pegylated hIL-10 can beadministered at a dose greater than 0.5 μg/kg/day, greater than 1.0μg/kg/day, greater than 2.5 μg/kg/day, greater than 5 μg/kg/day, greaterthan 7.5 μg/kg, greater than 10.0 μg/kg, greater than 12.5 μg/kg,greater than 15 μg/kg/day, greater than 17.5 μg/kg/day, greater than 20μg/kg/day, greater than 22.5 μg/kg/day, greater than 25 μg/kg/day,greater than 30 μg/kg/day, or greater than 35 μg/kg/day. In addition, byway of example, but not limitation, when the subject is a human,pegylated hIL-10 comprising a relatively small PEG (e.g., 5 kDamono-di-PEG-hIL-10) can be administered at a dose greater than 0.5μg/kg/day, greater than 0.75 μg/kg/day, greater than 1.0 μg/kg/day,greater than 1.25 μg/kg/day, greater than 1.5 μg/kg/day, greater than1.75 μg/kg/day, greater than 2.0 μg/kg/day, greater than 2.25 μg/kg/day,greater than 2.5 μg/kg/day, greater than 2.75 μg/kg/day, greater than3.0 μg/kg/day, greater than 3.25 μg/kg/day, greater than 3.5 μg/kg/day,greater than 3.75 μg/kg/day, greater than 4.0 μg/kg/day, greater than4.25 μg/kg/day, greater than 4.5 μg/kg/day, greater than 4.75 μg/kg/day,or greater than 5.0 μg/kg/day.

Although the preceding discussion regarding IL-10 serum concentrations,doses and treatment protocols that are necessary to achieve particularIL-10 serum concentrations, etc., pertains to monotherapy with an IL-10agent (e.g., PEG-IL-10), the skilled artisan (e.g., a pharmacologist) isable to determine the optimum dosing regimen(s) when an IL-10 agent(e.g., PEG-IL-10) is administered in combination with one or moreadditional therapies.

Methods of Production of IL-10

A polypeptide of the present disclosure can be produced by any suitablemethod, including non-recombinant (e.g., chemical synthesis) andrecombinant methods.

A. Chemical Synthesis

Where a polypeptide is chemically synthesized, the synthesis can proceedvia liquid-phase or solid-phase. Solid-phase peptide synthesis (SPPS)allows the incorporation of unnatural amino acids and/or peptide/proteinbackbone modification. Various forms of SPPS, such as9-fluorenylmethoxycarbonyl (Fmoc) and t-butyloxycarbonyl (Boc), areavailable for synthesizing polypeptides of the present disclosure.Details of the chemical syntheses are known in the art (e.g., Ganesan A.(2006) Mini Rev. Med. Chem. 6:3-10; and Camarero J. A. et al., (2005)Protein Pept Lett. 12:723-8).

Solid phase peptide synthesis can be performed as described hereafter.The alpha functions (Nα) and any reactive side chains are protected withacid-labile or base-labile groups. The protective groups are stableunder the conditions for linking amide bonds but can readily be cleavedwithout impairing the peptide chain that has formed. Suitable protectivegroups for the a-amino function include, but are not limited to, thefollowing: Boc, benzyloxycarbonyl (Z), O-chlorbenzyloxycarbonyl,bi-phenylisopropyloxycarbonyl, tert-amyloxycarbonyl (Amoc), α,α-dimethyl-3,5-dimethoxy-benzyloxycarbonyl, o-nitrosulfenyl,2-cyano-t-butoxy-carbonyl, Fmoc,1-(4,4-dimethyl-2,6-dioxocylohex-1-ylidene)ethyl (Dde) and the like.

Suitable side chain protective groups include, but are not limited to:acetyl, allyl (All), allyloxycarbonyl (Alloc), benzyl (Bzl),benzyloxycarbonyl (Z), t-butyloxycarbonyl (Boc), benzyloxymethyl (Bom),o-bromobenzyloxycarbonyl, t-butyl (tBu), t-butyldimethylsilyl,2-chlorobenzyl, 2-chlorobenzyloxycarbonyl, 2,6-dichlorobenzyl,cyclohexyl, cyclopentyl,1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde), isopropyl,4-methoxy-2,3-6-trimethylbenzylsulfonyl (Mtr),2,3,5,7,8-pentamethylchroman-6-sulfonyl (Pmc), pivalyl,tetrahydropyran-2-yl, tosyl (Tos), 2,4,6-trimethoxybenzyl,trimethylsilyl and trityl (Trt).

In the solid phase synthesis, the C-terminal amino acid is coupled to asuitable support material. Suitable support materials are those whichare inert towards the reagents and reaction conditions for the step-wisecondensation and cleavage reactions of the synthesis process and whichdo not dissolve in the reaction media being used. Examples ofcommercially-available support materials include styrene/divinylbenzenecopolymers which have been modified with reactive groups and/orpolyethylene glycol; chloromethylated styrene/divinylbenzene copolymers;hydroxymethylated or aminomethylated styrene/divinylbenzene copolymers;and the like. When preparation of the peptidic acid is desired,polystyrene (1%)-divinylbenzene or TentaGel® derivatized with4-benzyloxybenzyl-alcohol (Wang-anchor) or 2-chlorotrityl chloride canbe used. In the case of the peptide amide, polystyrene (1%)divinylbenzene or TentaGel® derivatized with5-(4′-aminomethyl)-3′,5′-dimethoxyphenoxy)valeric acid (PAL-anchor) orp-(2,4-dimethoxyphenyl-amino methyl)-phenoxy group (Rink amide anchor)can be used.

The linkage to the polymeric support can be achieved by reacting theC-terminal Fmoc-protected amino acid with the support material by theaddition of an activation reagent in ethanol, acetonitrile,N,N-dimethylformamide (DMF), dichloromethane, tetrahydrofuran,N-methylpyrrolidone or similar solvents at room temperature or elevatedtemperatures (e.g., between 40° C. and 60° C.) and with reaction timesof, e.g., 2 to 72 hours.

The coupling of the Nα-protected amino acid (e.g., the Fmoc amino acid)to the PAL, Wang or Rink anchor can, for example, be carried out withthe aid of coupling reagents such as N,N′-dicyclohexylcarbodiimide(DCC), N,N′-diisopropylcarbodiimide (DIC) or other carbodiimides,2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate(TBTU) or other uronium salts, O-acyl-ureas,benzotriazol-1-yl-tris-pyrrolidino-phosphonium hexafluorophosphate(PyBOP) or other phosphonium salts, N-hydroxysuccinimides, otherN-hydroxyimides or oximes in the presence or absence of1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole, e.g., with theaid of TBTU with addition of HOBt, with or without the addition of abase such as, for example, diisopropylethylamine (DIEA), triethylamineor N-methylmorpholine, e.g., diisopropylethylamine with reaction timesof 2 to 72 hours (e.g., 3 hours in a 1.5 to 3-fold excess of the aminoacid and the coupling reagents, for example, in a 2-fold excess and attemperatures between about 10° C. and 50° C., for example, 25° C. in asolvent such as dimethylformamide, N-methylpyrrolidone ordichloromethane, e.g., dimethylformamide).

Instead of the coupling reagents, it is also possible to use the activeesters (e.g., pentafluorophenyl, p-nitrophenyl or the like), thesymmetric anhydride of the Nα-Fmoc-amino acid, its acid chloride or acidfluoride, under the conditions described above.

The Nα-protected amino acid (e.g., the Fmoc amino acid) can be coupledto the 2-chlorotrityl resin in dichloromethane with the addition of DIEAand having reaction times of 10 to 120 minutes, e.g., 20 minutes, but isnot limited to the use of this solvent and this base.

The successive coupling of the protected amino acids can be carried outaccording to conventional methods in peptide synthesis, typically in anautomated peptide synthesizer. After cleavage of the Nα-Fmoc protectivegroup of the coupled amino acid on the solid phase by treatment with,e.g., piperidine (10% to 50%) in dimethylformamide for 5 to 20 minutes,e.g., 2×2 minutes with 50% piperidine in DMF and 1×15 minutes with 20%piperidine in DMF, the next protected amino acid in a 3 to 10-foldexcess, e.g., in a 10-fold excess, is coupled to the previous amino acidin an inert, non-aqueous, polar solvent such as dichloromethane, DMF ormixtures of the two and at temperatures between about 10° C. and 50° C.,e.g., at 25° C. The previously mentioned reagents for coupling the firstNα-Fmoc amino acid to the PAL, Wang or Rink anchor are suitable ascoupling reagents. Active esters of the protected amino acid, orchlorides or fluorides or symmetric anhydrides thereof can also be usedas an alternative.

At the end of the solid phase synthesis, the peptide is cleaved from thesupport material while simultaneously cleaving the side chain protectinggroups. Cleavage can be carried out with trifluoroacetic acid or otherstrongly acidic media with addition of 5%-20% V/V of scavengers such asdimethylsulfide, ethylmethylsulfide, thioanisole, thiocresol, m-cresol,anisole ethanedithiol, phenol or water, e.g., 15% v/vdimethylsulfide/ethanedithiol/m-cresol 1:1:1, within 0.5 to 3 hours,e.g., 2 hours. Peptides with fully protected side chains are obtained bycleaving the 2-chlorotrityl anchor with glacial aceticacid/trifluoroethanol/dichloromethane 2:2:6. The protected peptide canbe purified by chromatography on silica gel. If the peptide is linked tothe solid phase via the Wang anchor and if it is intended to obtain apeptide with a C-terminal alkylamidation, the cleavage can be carriedout by aminolysis with an alkylamine or fluoroalkylamine. The aminolysisis carried out at temperatures between about −10° C. and 50° C. (e.g.,about 25° C.), and reaction times between about 12 and 24 hours (e.g.,about 18 hours). In addition the peptide can be cleaved from the supportby re-esterification, e.g., with methanol.

The acidic solution that is obtained can be admixed with a 3 to 20-foldamount of cold ether or n-hexane, e.g., a 10-fold excess of diethylether, in order to precipitate the peptide and hence to separate thescavengers and cleaved protective groups that remain in the ether. Afurther purification can be carried out by re-precipitating the peptideseveral times from glacial acetic acid. The precipitate that is obtainedcan be taken up in water or tert-butanol or mixtures of the twosolvents, e.g., a 1:1 mixture of tert-butanol/water, and freeze-dried.

The peptide obtained can be purified by various chromatographic methods,including ion exchange over a weakly basic resin in the acetate form;hydrophobic adsorption chromatography on non-derivatizedpolystyrene/divinylbenzene copolymers (e.g., Amberlite® XAD); adsorptionchromatography on silica gel; ion exchange chromatography, e.g., oncarboxymethyl cellulose; distribution chromatography, e.g., on Sephadex®G-25; countercurrent distribution chromatography; or high pressureliquid chromatography (HPLC) e.g., reversed-phase HPLC on octyl oroctadecylsilylsilica (ODS) phases.

B. Recombinant Production

Methods describing the preparation of human and mouse IL-10 can be foundin, for example, U.S. Pat. No. 5,231,012, which teaches methods for theproduction of proteins having IL-10 activity, including recombinant andother synthetic techniques. IL-10 can be of viral origin, and thecloning and expression of a viral IL-10 from Epstein Barr virus (BCRF1protein) is disclosed in Moore et al., (1990) Science 248:1230. IL-10can be obtained in a number of ways using standard techniques known inthe art, such as those described herein. Recombinant human IL-10 is alsocommercially available, e.g., from PeproTech, Inc., Rocky Hill, N.J.

Where a polypeptide is produced using recombinant techniques, thepolypeptide can be produced as an intracellular protein or as a secretedprotein, using any suitable construct and any suitable host cell, whichcan be a prokaryotic or eukaryotic cell, such as a bacterial (e.g., E.coli) or a yeast host cell, respectively. Other examples of eukaryoticcells that can be used as host cells include insect cells, mammaliancells, and/or plant cells. Where mammalian host cells are used, they caninclude human cells (e.g., HeLa, 293, H9 and Jurkat cells); mouse cells(e.g., NIH3T3, L cells, and C127 cells); primate cells (e.g., Cos 1, Cos7 and CV1); and hamster cells (e.g., Chinese hamster ovary (CHO) cells).

A variety of host-vector systems suitable for the expression of apolypeptide can be employed according to standard procedures known inthe art. See, e.g., Sambrook et al., 1989 Current Protocols in MolecularBiology Cold Spring Harbor Press, New York; and Ausubel et al. 1995Current Protocols in Molecular Biology, Eds. Wiley and Sons. Methods forintroduction of genetic material into host cells include, for example,transformation, electroporation, conjugation, calcium phosphate methodsand the like. The method for transfer can be selected so as to providefor stable expression of the introduced polypeptide-encoding nucleicacid. The polypeptide-encoding nucleic acid can be provided as aninheritable episomal element (e.g., a plasmid) or can be genomicallyintegrated. A variety of appropriate vectors for use in production of apolypeptide of interest are commercially available.

Vectors can provide for extrachromosomal maintenance in a host cell orcan provide for integration into the host cell genome. The expressionvector provides transcriptional and translational regulatory sequences,and can provide for inducible or constitutive expression where thecoding region is operably-linked under the transcriptional control ofthe transcriptional initiation region, and a transcriptional andtranslational termination region. In general, the transcriptional andtranslational regulatory sequences can include, but are not limited to,promoter sequences, ribosomal binding sites, transcriptional start andstop sequences, translational start and stop sequences, and enhancer oractivator sequences. Promoters can be either constitutive or inducible,and can be a strong constitutive promoter (e.g., T7).

Expression constructs generally have convenient restriction siteslocated near the promoter sequence to provide for the insertion ofnucleic acid sequences encoding proteins of interest. A selectablemarker operative in the expression host can be present to facilitateselection of cells containing the vector. Moreover, the expressionconstruct can include additional elements. For example, the expressionvector can have one or two replication systems, thus allowing it to bemaintained in organisms, for example, in mammalian or insect cells forexpression and in a prokaryotic host for cloning and amplification. Inaddition, the expression construct can contain a selectable marker geneto allow the selection of transformed host cells. Selectable genes arewell known in the art and will vary with the host cell used.

Isolation and purification of a protein can be accomplished according tomethods known in the art. For example, a protein can be isolated from alysate of cells genetically modified to express the proteinconstitutively and/or upon induction, or from a synthetic reactionmixture by immunoaffinity purification, which generally involvescontacting the sample with an anti-protein antibody, washing to removenon-specifically bound material, and eluting the specifically boundprotein. The isolated protein can be further purified by dialysis andother methods normally employed in protein purification. In oneembodiment, the protein can be isolated using metal chelatechromatography methods. Proteins can contain modifications to facilitateisolation.

The polypeptides can be prepared in substantially pure or isolated form(e.g., free from other polypeptides). The polypeptides can be present ina composition that is enriched for the polypeptide relative to othercomponents that can be present (e.g., other polypeptides or other hostcell components). For example, purified polypeptide can be provided suchthat the polypeptide is present in a composition that is substantiallyfree of other expressed proteins, e.g., less than about 90%, less thanabout 60%, less than about 50%, less than about 40%, less than about30%, less than about 20%, less than about 10%, less than about 5%, orless than about 1%.

An IL-10 polypeptide can be generated using recombinant techniques tomanipulate different IL-10-related nucleic acids known in the art toprovide constructs capable of encoding the IL-10 polypeptide. It will beappreciated that, when provided a particular amino acid sequence, theordinary skilled artisan will recognize a variety of different nucleicacid molecules encoding such amino acid sequence in view of herbackground and experience in, for example, molecular biology.

Amide Bond Substitutions

In some cases, IL-10 includes one or more linkages other than peptidebonds, e.g., at least two adjacent amino acids are joined via a linkageother than an amide bond. For example, in order to reduce or eliminateundesired proteolysis or other means of degradation, and/or to increaseserum stability, and/or to restrict or increase conformationalflexibility, one or more amide bonds within the backbone of IL-10 can besubstituted.

In another example, one or more amide linkages (—CO—NH—) in IL-10 can bereplaced with a linkage which is an isostere of an amide linkage, suchas —CH₂NH—, —CH₂S—, —CH₂CH₂—, —CH═CH— (cis and trans), —COCH₂—,—CH(OH)CH₂— or —CH₂SO—. One or more amide linkages in IL-10 can also bereplaced by, for example, a reduced isostere pseudopeptide bond. SeeCouder et al. (1993) Int. J. Peptide Protein Res. 41:181-184. Suchreplacements and how to effect them are known to those of ordinary skillin the art.

Amino Acid Substitutions

One or more amino acid substitutions can be made in an IL-10polypeptide. The following are non-limiting examples:

a) substitution of alkyl-substituted hydrophobic amino acids, includingalanine, leucine, isoleucine, valine, norleucine, (S)-2-aminobutyricacid, (S)-cyclohexylalanine or other simple alpha-amino acidssubstituted by an aliphatic side chain from C1-C10 carbons includingbranched, cyclic and straight chain alkyl, alkenyl or alkynylsubstitutions;

b) substitution of aromatic-substituted hydrophobic amino acids,including phenylalanine, tryptophan, tyrosine, sulfotyrosine,biphenylalanine, 1-naphthylalanine, 2-naphthylalanine,2-benzothienylalanine, 3-benzothienylalanine, histidine, includingamino, alkylamino, dialkylamino, aza, halogenated (fluoro, chloro,bromo, or iodo) or alkoxy (from C₁-C₄)-substituted forms of theabove-listed aromatic amino acids, illustrative examples of which are:2-, 3- or 4-aminophenylalanine, 2-, 3- or 4-chlorophenylalanine, 2-, 3-or 4-methylphenylalanine, 2-, 3- or 4-methoxyphenylalanine, 5-amino-,5-chloro-, 5-methyl- or 5-methoxytryptophan, 2′-, 3′-, or 4′-amino-,2′-, 3′-, or 4′-chloro-, 2, 3, or 4-biphenylalanine, 2′-, 3′-, or4′-methyl-, 2-, 3- or 4-biphenylalanine, and 2- or 3-pyridylalanine;

c) substitution of amino acids containing basic side chains, includingarginine, lysine, histidine, ornithine, 2,3-diaminopropionic acid,homoarginine, including alkyl, alkenyl, or aryl-substituted (from C₁-C₁₀branched, linear, or cyclic) derivatives of the previous amino acids,whether the substituent is on the heteroatoms (such as the alphanitrogen, or the distal nitrogen or nitrogens, or on the alpha carbon,in the pro-R position for example. Compounds that serve as illustrativeexamples include: N-epsilon-isopropyl-lysine,3-(4-tetrahydropyridyl)-glycine, 3-(4-tetrahydropyridyl)-alanine,N,N-gamma, gamma′-diethyl-homoarginine. Included also are compounds suchas alpha-methyl-arginine, alpha-methyl-2,3-diaminopropionic acid,alpha-methyl-histidine, alpha-methyl-ornithine where the alkyl groupoccupies the pro-R position of the alpha-carbon. Also included are theamides formed from alkyl, aromatic, heteroaromatic (where theheteroaromatic group has one or more nitrogens, oxygens or sulfur atomssingly or in combination), carboxylic acids or any of the manywell-known activated derivatives such as acid chlorides, active esters,active azolides and related derivatives, and lysine, ornithine, or2,3-diaminopropionic acid;

d) substitution of acidic amino acids, including aspartic acid, glutamicacid, homoglutamic acid, tyrosine, alkyl, aryl, arylalkyl, andheteroaryl sulfonamides of 2,4-diaminopriopionic acid, ornithine orlysine and tetrazole-substituted alkyl amino acids;

e) substitution of side chain amide residues, including asparagine,glutamine, and alkyl or aromatic substituted derivatives of asparagineor glutamine; and

f) substitution of hydroxyl-containing amino acids, including serine,threonine, homoserine, 2,3-diaminopropionic acid, and alkyl or aromaticsubstituted derivatives of serine or threonine.

In some cases, IL-10 comprises one or more naturally occurringnon-genetically encoded L-amino acids, synthetic L-amino acids, orD-enantiomers of an amino acid. For example, IL-10 can comprise onlyD-amino acids. For example, an IL-10 polypeptide can comprise one ormore of the following residues: hydroxyproline, β-alanine,o-aminobenzoic acid, m-aminobenzoic acid, p-aminobenzoic acid,m-aminomethylbenzoic acid, 2,3-diaminopropionic acid, α-aminoisobutyricacid, N-methylglycine (sarcosine), ornithine, citrulline,t-butylalanine, t-butylglycine, N-methylisoleucine, phenylglycine,cyclohexylalanine, norleucine, naphthylalanine, pyridylalanine3-benzothienyl alanine, 4-chlorophenylalanine, 2-fluorophenylalanine,3-fluorophenylalanine, 4-fluorophenylalanine, penicillamine,1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, β-2-thienylalanine,methionine sulfoxide, homoarginine, N-acetyl lysine, 2,4-diamino butyricacid, rho-aminophenylalanine, N-methylvaline, homocysteine, homoserine,ε-amino hexanoic acid, ω-aminohexanoic acid, ω-aminoheptanoic acid,ω-aminooctanoic acid, ω-aminodecanoic acid, ω-aminotetradecanoic acid,cyclohexylalanine, α,γ-diaminobutyric acid, α,β-diaminopropionic acid,6-amino valeric acid, and 2,3-diaminobutyric acid.

Additional Modifications

A cysteine residue or a cysteine analog can be introduced into an IL-10polypeptide to provide for linkage to another peptide via a disulfidelinkage or to provide for cyclization of the IL-10 polypeptide. Methodsof introducing a cysteine or cysteine analog are known in the art; see,e.g., U.S. Pat. No. 8,067,532.

An IL-10 polypeptide can be cyclized. One or more cysteines or cysteineanalogs can be introduced into an IL-10 polypeptide, where theintroduced cysteine or cysteine analog can form a disulfide bond with asecond introduced cysteine or cysteine analog. Other means ofcyclization include introduction of an oxime linker or a lanthioninelinker; see, e.g., U.S. Pat. No. 8,044,175. Any combination of aminoacids (or non-amino acid moieties) that can form a cyclizing bond can beused and/or introduced. A cyclizing bond can be generated with anycombination of amino acids (or with an amino acid and —(CH₂)_(n)—CO— or—(CH₂)_(n)—C₆H₄—CO—) with functional groups which allow for theintroduction of a bridge. Some examples are disulfides, disulfidemimetics such as the —(CH₂)_(n)— carba bridge, thioacetal, thioetherbridges (cystathionine or lanthionine) and bridges containing esters andethers. In these examples, n can be any integer, but is frequently lessthan ten.

Other modifications include, for example, an N-alkyl (or aryl)substitution (ψ[CONR]), or backbone crosslinking to construct lactamsand other cyclic structures. Other derivatives include C-terminalhydroxymethyl derivatives, o-modified derivatives (e.g., C-terminalhydroxymethyl benzyl ether), N-terminally modified derivatives includingsubstituted amides such as alkylamides and hydrazides.

In some cases, one or more L-amino acids in an IL-10 polypeptide isreplaced with one or more D-amino acids.

In some cases, an IL-10 polypeptide is a retroinverso analog (see, e.g.,Sela and Zisman (1997) FASEB J. 11:449). Retro-inverso peptide analogsare isomers of linear polypeptides in which the direction of the aminoacid sequence is reversed (retro) and the chirality, D- or L-, of one ormore amino acids therein is inverted (inverso), e.g., using D-aminoacids rather than L-amino acids. [See, e.g., Jameson et al. (1994)Nature 368:744; and Brady et al. (1994) Nature 368:692].

An IL-10 polypeptide can include a “Protein Transduction Domain” (PTD),which refers to a polypeptide, polynucleotide, carbohydrate, or organicor inorganic molecule that facilitates traversing a lipid bilayer,micelle, cell membrane, organelle membrane, or vesicle membrane. A PTDattached to another molecule facilitates the molecule traversing amembrane, for example going from extracellular space to intracellularspace, or cytosol to within an organelle. In some embodiments, a PTD iscovalently linked to the amino terminus of an IL-10 polypeptide, whilein other embodiments, a PTD is covalently linked to the carboxylterminus of an IL-10 polypeptide. Exemplary protein transduction domainsinclude, but are not limited to, a minimal undecapeptide proteintransduction domain (corresponding to residues 47-57 of HIV-1 TATcomprising YGRKKRRQRRR; SEQ ID NO:1); a polyarginine sequence comprisinga number of arginine residues sufficient to direct entry into a cell(e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50 arginines); a VP22 domain(Zender et al. (2002) Cancer Gene Ther. 9(6):489-96); a DrosophilaAntennapedia protein transduction domain (Noguchi et al. (2003) Diabetes52(7):1732-1737); a truncated human calcitonin peptide (Trehin et al.(2004) Pharm. Research 21:1248-1256); polylysine (Wender et al. (2000)Proc. Natl. Acad. Sci. USA 97:13003-13008); RRQRRTSKLMKR (SEQ ID NO:2);Transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:3);KALAWEAKLAKALAKALAKHLAKALAKALKCEA (SEQ ID NO:4); and RQIKIWFQNRRMKWKK(SEQ ID NO:5). Exemplary PTDs include, but are not limited to,YGRKKRRQRRR (SEQ ID NO:1), RKKRRQRRR (SEQ ID NO:6); an argininehomopolymer of from 3 arginine residues to 50 arginine residues;exemplary PTD domain amino acid sequences include, but are not limitedto, any of the following: YGRKKRRQRRR (SEQ ID NO:1); RKKRRQRR (SEQ IDNO:7); YARAAARQARA (SEQ ID NO:8); THRLPRRRRRR (SEQ ID NO:9); andGGRRARRRRRR (SEQ ID NO:10).

The carboxyl group COR₃ of the amino acid at the C-terminal end of anIL-10 polypeptide can be present in a free form (R₃═OH) or in the formof a physiologically-tolerated alkaline or alkaline earth salt such as,e.g., a sodium, potassium or calcium salt. The carboxyl group can alsobe esterified with primary, secondary or tertiary alcohols such as,e.g., methanol, branched or unbranched C1-C6-alkyl alcohols, e.g., ethylalcohol or tert-butanol. The carboxyl group can also be amidated withprimary or secondary amines such as ammonia, branched or unbranchedC1-C6-alkylamines or C1-C6 di-alkylamines, e.g., methylamine ordimethylamine.

The amino group of the amino acid NR1R2 at the N-terminus of an IL-10polypeptide can be present in a free form (R1=H and R₂═H) or in the formof a physiologically-tolerated salt such as, e.g., a chloride oracetate. The amino group can also be acetylated with acids such thatR₁═H and R₂=acetyl, trifluoroacetyl, or adamantyl. The amino group canbe present in a form protected by amino-protecting groups conventionallyused in peptide chemistry, such as those provided above (e.g., Fmoc,Benzyloxy-carbonyl (Z), Boc, and Alloc). The amino group can beN-alkylated in which R₁ and/or R₂═C₁-C₆ alkyl or C₂-C₈ alkenyl or C₇-C₉aralkyl. Alkyl residues can be straight-chained, branched or cyclic(e.g., ethyl, isopropyl and cyclohexyl, respectively).

Particular Modifications to Enhance and/or Mimic IL-10 Function

It is frequently beneficial, and sometimes imperative, to improve one ofmore physical properties of the treatment modalities disclosed herein(e.g., IL-10) and/or the manner in which they are administered.Improvements of physical properties include, for example, modulatingimmunogenicity; methods of increasing water solubility, bioavailability,serum half-life, and/or therapeutic half-life; and/or modulatingbiological activity. Certain modifications can also be useful to, forexample, raise of antibodies for use in detection assays (e.g., epitopetags) and to provide for ease of protein purification. Such improvementsmust generally be imparted without adversely impacting the bioactivityof the treatment modality and/or increasing its immunogenicity.

Pegylation of IL-10 is one particular modification contemplated by thepresent disclosure, while other modifications include, but are notlimited to, glycosylation (N- and O-linked); polysialylation; albuminfusion molecules comprising serum albumin (e.g., human serum albumin(HSA), cyno serum albumin, or bovine serum albumin (BSA)); albuminbinding through, for example a conjugated fatty acid chain (acylation);and Fc-fusion proteins.

Pegylation:

The clinical effectiveness of protein therapeutics is often limited byshort plasma half-life and susceptibility to protease degradation.Studies of various therapeutic proteins (e.g., filgrastim) have shownthat such difficulties can be overcome by various modifications,including conjugating or linking the polypeptide sequence to any of avariety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG),polypropylene glycol, or polyoxyalkylenes. This is frequently effectedby a linking moiety covalently bound to both the protein and thenonproteinaceous polymer, e.g., a PEG. Such PEG-conjugated biomoleculeshave been shown to possess clinically useful properties, includingbetter physical and thermal stability, protection against susceptibilityto enzymatic degradation, increased solubility, longer in vivocirculating half-life and decreased clearance, reduced immunogenicityand antigenicity, and reduced toxicity.

In addition to the beneficial effects of pegylation on pharmacokineticparameters, pegylation itself can enhance activity. For example,PEG-IL-10 has been shown to be more efficacious against certain cancersthan unpegylated IL-10 (see, e.g., EP 206636A2).

PEGs suitable for conjugation to a polypeptide sequence are generallysoluble in water at room temperature, and have the general formulaR(O—CH₂—CH₂)_(n)O—R, where R is hydrogen or a protective group such asan alkyl or an alkanol group, and where n is an integer from 1 to 1000.When R is a protective group, it generally has from 1 to 8 carbons. ThePEG conjugated to the polypeptide sequence can be linear or branched.Branched PEG derivatives, “star-PEGs” and multi-armed PEGs arecontemplated by the present disclosure. A molecular weight of the PEGused in the present disclosure is not restricted to any particularrange, and examples are set forth elsewhere herein; by way of example,certain embodiments have molecular weights between 5 kDa and 20 kDa,while other embodiments have molecular weights between 4 kDa and 10 kDa.

The present disclosure also contemplates compositions of conjugateswherein the PEGs have different n values, and thus the various differentPEGs are present in specific ratios. For example, some compositionscomprise a mixture of conjugates where n=1, 2, 3 and 4. In somecompositions, the percentage of conjugates where n=1 is 18-25%, thepercentage of conjugates where n=2 is 50-66%, the percentage ofconjugates where n=3 is 12-16%, and the percentage of conjugates wheren=4 is up to 5%. Such compositions can be produced by reactionconditions and purification methods know in the art. Exemplary reactionconditions are described throughout the specification. Cation exchangechromatography can be used to separate conjugates, and a fraction isthen identified which contains the conjugate having, for example, thedesired number of PEGs attached, purified free from unmodified proteinsequences and from conjugates having other numbers of PEGs attached.

Pegylation most frequently occurs at the alpha amino group at theN-terminus of the polypeptide, the epsilon amino group on the side chainof lysine residues, and the imidazole group on the side chain ofhistidine residues. Since most recombinant polypeptides possess a singlealpha and a number of epsilon amino and imidazole groups, numerouspositional isomers can be generated depending on the linker chemistry.General pegylation strategies known in the art can be applied herein.

Two widely used first generation activated monomethoxy PEGs (mPEGs) aresuccinimdyl carbonate PEG (SC-PEG; see, e.g., Zalipsky, et al. (1992)Biotehnol. Appl. Biochem 15:100-114; and Miron and Wilcheck (1993)Bio-conjug. Chem. 4:568-569) and benzotriazole carbonate PEG (BTC-PEG;see, e.g., Dolence, et al. U.S. Pat. No. 5,650,234), which reactpreferentially with lysine residues to form a carbamate linkage, but arealso known to react with histidine and tyrosine residues. The linkage tohistidine residues on certain molecules (e.g., IFNα) has been shown tobe a hydrolytically unstable imidazolecarbamate linkage (see, e.g., Leeand McNemar, U.S. Pat. No. 5,985,263). Second generation pegylationtechnology has been designed to avoid these unstable linkages as well asthe lack of selectivity in residue reactivity. Use of a PEG-aldehydelinker targets a single site on the N-terminus of a polypeptide throughreductive amination.

PEG can be bound to a polypeptide of the present disclosure via aterminal reactive group (a “spacer”) which mediates a bond between thefree amino or carboxyl groups of one or more of the polypeptidesequences and polyethylene glycol. The PEG having the spacer which canbe bound to the free amino group includes N-hydroxysuccinylimidepolyethylene glycol, which can be prepared by activating succinic acidester of polyethylene glycol with N-hydroxysuccinylimide. Anotheractivated polyethylene glycol which can be bound to a free amino groupis 2,4-bis(O-methoxypolyethyleneglycol)-6-chloro-s-triazine, which canbe prepared by reacting polyethylene glycol monomethyl ether withcyanuric chloride. The activated polyethylene glycol which is bound tothe free carboxyl group includes polyoxyethylenediamine.

Conjugation of one or more of the polypeptide sequences of the presentdisclosure to PEG having a spacer can be carried out by variousconventional methods. For example, the conjugation reaction can becarried out in solution at a pH of from 5 to 10, at temperature from 4°C. to room temperature, for 30 minutes to 20 hours, utilizing a molarratio of reagent to protein of from 4:1 to 30:1. Reaction conditions canbe selected to direct the reaction towards producing predominantly adesired degree of substitution. In general, low temperature, low pH(e.g., pH=5), and short reaction time tend to decrease the number ofPEGs attached, whereas high temperature, neutral to high pH (e.g.,pH≥7), and longer reaction time tend to increase the number of PEGsattached. Various means known in the art can be used to terminate thereaction. In some embodiments the reaction is terminated by acidifyingthe reaction mixture and freezing at, e.g., −20° C. Pegylation ofvarious molecules is discussed in, for example, U.S. Pat. Nos.5,252,714; 5,643,575; 5,919,455; 5,932,462; and 5,985,263. PEG-IL-10 isdescribed in, e.g., U.S. Pat. No. 7,052,686. Specific reactionconditions contemplated for use herein are set forth in the Experimentalsection.

The present disclosure also contemplates the use of PEG mimetics.Recombinant PEG mimetics have been developed that retain the attributesof PEG (e.g., enhanced serum half-life) while conferring severaladditional advantageous properties. By way of example, simplepolypeptide chains (comprising, for example, Ala, Glu, Gly, Pro, Ser andThr) capable of forming an extended conformation similar to PEG can beproduced recombinantly already fused to the peptide or protein drug ofinterest (e.g., Amunix's XTEN technology; Mountain View, Calif.). Thisobviates the need for an additional conjugation step during themanufacturing process. Moreover, established molecular biologytechniques enable control of the side chain composition of thepolypeptide chains, allowing optimization of immunogenicity andmanufacturing properties.

Glycosylation:

For purposes of the present disclosure, “glycosylation” is meant tobroadly refer to the enzymatic process that attaches glycans toproteins, lipids or other organic molecules. The use of the term“glycosylation” in conjunction with the present disclosure is generallyintended to mean adding or deleting one or more carbohydrate moieties(either by removing the underlying glycosylation site or by deleting theglycosylation by chemical and/or enzymatic means), and/or adding one ormore glycosylation sites that may or may not be present in the nativesequence. In addition, the phrase includes qualitative changes in theglycosylation of the native proteins involving a change in the natureand proportions of the various carbohydrate moieties present.

Glycosylation can dramatically affect the physical properties (e.g.,solubility) of polypeptides such as IL-10 and can also be important inprotein stability, secretion, and subcellular localization. Glycosylatedpolypeptides can also exhibit enhanced stability or can improve one ormore pharmacokinetic properties, such as half-life. In addition,solubility improvements can, for example, enable the generation offormulations more suitable for pharmaceutical administration thanformulations comprising the non-glycosylated polypeptide.

Addition of glycosylation sites can be accomplished by altering theamino acid sequence. The alteration to the polypeptide can be made, forexample, by the addition of, or substitution by, one or more serine orthreonine residues (for O-linked glycosylation sites) or asparagineresidues (for N-linked glycosylation sites). The structures of N-linkedand O-linked oligosaccharides and the sugar residues found in each typecan be different. One type of sugar that is commonly found on both isN-acetylneuraminic acid (hereafter referred to as sialic acid). Sialicacid is usually the terminal residue of both N-linked and 0-linkedoligosaccharides and, by virtue of its negative charge, can conferacidic properties to the glycoprotein. A particular embodiment of thepresent disclosure comprises the generation and use of N-glycosylationvariants.

The polypeptide sequences of the present disclosure can optionally bealtered through changes at the nucleic acid level, particularly bymutating the nucleic acid encoding the polypeptide at preselected basessuch that codons are generated that will translate into the desiredamino acids.

Polysialylation:

The present disclosure also contemplates the use of polysialylation, theconjugation of polypeptides to the naturally occurring, biodegradablea-(2→8) linked polysialic acid (“PSA”) in order to improve thepolypeptides' stability and in vivo pharmacokinetics. PSA is abiodegradable, non-toxic natural polymer that is highly hydrophilic,giving it a high apparent molecular weight in the blood which increasesits serum half-life. In addition, polysialylation of a range of peptideand protein therapeutics has led to markedly reduced proteolysis,retention of activity in vivo activity, and reduction in immunogenicityand antigenicity (see, e.g., G. Gregoriadis et al., Int. J.Pharmaceutics 300(1-2):125-30). Various techniques for site-specificpolysialylation are available (see, e.g., T. Lindhout et al., PNAS108(18)7397-7402 (2011)).

Albumin Fusion:

Additional suitable components and molecules for conjugation includealbumins such as human serum albumin (HSA), cyno serum albumin, andbovine serum albumin (BSA).

According to the present disclosure, albumin can be conjugated to a drugmolecule (e.g., a polypeptide described herein) at the carboxylterminus, the amino terminus, both the carboxyl and amino termini, andinternally (see, e.g., U.S. Pat. Nos. 5,876,969 and 7,056,701).

In the HSA—drug molecule conjugates contemplated by the presentdisclosure, various forms of albumin can be used, such as albuminsecretion pre-sequences and variants thereof, fragments and variantsthereof, and HSA variants. Such forms generally possess one or moredesired albumin activities. In additional embodiments, the presentdisclosure involves fusion proteins comprising a polypeptide drugmolecule fused directly or indirectly to albumin, an albumin fragment,and albumin variant, etc., wherein the fusion protein has a higherplasma stability than the unfused drug molecule and/or the fusionprotein retains the therapeutic activity of the unfused drug molecule.In some embodiments, the indirect fusion is effected by a linker, suchas a peptide linker or modified version thereof.

As alluded to above, fusion of albumin to one or more polypeptides ofthe present disclosure can, for example, be achieved by geneticmanipulation, such that the nucleic acid coding for HSA, or a fragmentthereof, is joined to the nucleic acid coding for the one or morepolypeptide sequences.

Alternative Albumin Binding Strategies:

Several albumin—binding strategies have been developed as alternativesto direct fusion and can be used with the IL-10 agents described herein.By way of example, the present disclosure contemplates albumin bindingthrough a conjugated fatty acid chain (acylation) and fusion proteinswhich comprise an albumin binding domain (ABD) polypeptide sequence andthe sequence of one or more of the polypeptides described herein.

Conjugation with Other Molecules:

Additional suitable components and molecules for conjugation include,for example, thyroglobulin; tetanus toxoid; Diphtheria toxoid; polyaminoacids such as poly(D-lysine:D-glutamic acid); VP6 polypeptides ofrotaviruses; influenza virus hemaglutinin, influenza virusnucleoprotein; Keyhole Limpet Hemocyanin (KLH); and hepatitis B viruscore protein and surface antigen; or any combination of the foregoing.

Thus, the present disclosure contemplates conjugation of one or moreadditional components or molecules at the N- and/or C-terminus of apolypeptide sequence, such as another polypeptide (e.g., a polypeptidehaving an amino acid sequence heterologous to the subject polypeptide),or a carrier molecule. Thus, an exemplary polypeptide sequence can beprovided as a conjugate with another component or molecule.

An IL-10 polypeptide can also be conjugated to large, slowly metabolizedmacromolecules such as proteins; polysaccharides, such as sepharose,agarose, cellulose, or cellulose beads; polymeric amino acids such aspolyglutamic acid, or polylysine; amino acid copolymers; inactivatedvirus particles; inactivated bacterial toxins such as toxoid fromdiphtheria, tetanus, cholera, or leukotoxin molecules; inactivatedbacteria; and dendritic cells. Such conjugated forms can, if desired, beused to produce antibodies against a polypeptide of the presentdisclosure.

Additional candidate components and molecules for conjugation includethose suitable for isolation or purification. Particular non-limitingexamples include binding molecules, such as biotin (biotin-avidinspecific binding pair), an antibody, a receptor, a ligand, a lectin, ormolecules that comprise a solid support, including, for example, plasticor polystyrene beads, plates or beads, magnetic beads, test strips, andmembranes.

Fc-Fusion Molecules:

In certain embodiments, the amino- or carboxyl-terminus of a polypeptidesequence of the present disclosure can be fused with an immunoglobulinFc region (e.g., human Fc) to form a fusion conjugate (or fusionmolecule). Fc fusion conjugates have been shown to increase the systemichalf-life of biopharmaceuticals, and thus the biopharmaceutical productcan require less frequent administration.

Fc binds to the neonatal Fc receptor (FcRn) in endothelial cells thatline the blood vessels, and, upon binding, the Fc fusion molecule isprotected from degradation and re-released into the circulation, keepingthe molecule in circulation longer. This Fc binding is believed to bethe mechanism by which endogenous IgG retains its long plasma half-life.More recent Fc-fusion technology links a single copy of abiopharmaceutical to the Fc region of an antibody to optimize thepharmacokinetic and pharmacodynamic properties of the biopharmaceuticalas compared to traditional Fc-fusion conjugates.

Other Modifications:

The present disclosure contemplates the use of other modifications,currently known or developed in the future, of IL-10 to improve one ormore properties. Examples include hesylation, various aspects of whichare described in, for example, U.S. Patent Appln. Nos. 2007/0134197 and2006/0258607, and fusion molecules comprising SUMO as a fusion tag(LifeSensors, Inc.; Malvern, Pa.).

Linkers:

Linkers and their use have been described above. Any of the foregoingcomponents and molecules used to modify the polypeptide sequences of thepresent disclosure may optionally be conjugated via a linker. Suitablelinkers include “flexible linkers” which are generally of sufficientlength to permit some movement between the modified polypeptidesequences and the linked components and molecules. The linker moleculesare generally about 6-50 atoms long. The linker molecules may also be,for example, aryl acetylene, ethylene glycol oligomers containing 2-10monomer units, diamines, diacids, amino acids, or combinations thereof.Suitable linkers can be readily selected and can be of any suitablelength, such as 1 amino acid (e.g., Gly), 2, 3, 4, 5, 6, 7, 8, 9, 10,10-20, 20-30, 30-50 or more than 50 amino acids.

Examples of flexible linkers include glycine polymers (G)_(n),glycine-alanine polymers, alanine-serine polymers, glycine-serinepolymers (for example, (GmSo)n, (GSGGS)_(n) (SEQ ID NO:11),(G_(m)S_(o)G_(m))_(n), (G_(m)S_(o)G_(m)S_(o)G_(m))_(n) (SEQ ID NO:12),(GSGGS_(m))_(n) (SEQ ID NO:11), (GSGS_(m)G)_(n) (SEQ ID NO:12) and(GGGS_(m))_(n) (SEQ ID NO:13), and combinations thereof, where m, n, ando are each independently selected from an integer of at least 1 to 20,e.g., 1-18, 2-16, 3-14, 4-12, 5-10, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10),and other flexible linkers. Glycine and glycine-serine polymers arerelatively unstructured, and therefore may serve as a neutral tetherbetween components. Examples of flexible linkers include, but are notlimited to GGSG (SEQ ID NO:14), GGSGG (SEQ ID NO:15), GSGSG (SEQ IDNO:12), GSGGG (SEQ ID NO:16), GGGSG (SEQ ID NO:17), and GSSSG (SEQ IDNO:18).

Additional examples of flexible linkers include glycine polymers (G)_(n)or glycine-serine polymers (e.g., (GS)_(n), (GSGGS)_(n) (SEQ ID NO:11),(GGGS)_(n) (SEQ ID NO:13) and (GGGGS)_(n) (SEQ ID NO:19), where n=1 to50, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10-20, 20-30, 30-50).Exemplary flexible linkers include, but are not limited to GGGS (SEQ IDNO:13), GGGGS (SEQ ID NO:19), GGSG (SEQ ID NO:14), GGSGG (SEQ ID NO:15),GSGSG (SEQ ID NO:12), GSGGG (SEQ ID NO:16), GGGSG (SEQ ID NO:17), andGSSSG (SEQ ID NO:18). A multimer (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,10-20, 20-30, or 30-50) of these linker sequences may be linked togetherto provide flexible linkers that may be used to conjugate a heterologousamino acid sequence to the IL-10 agents disclosed herein. As describedherein, the heterologous amino acid sequence may be a signal sequenceand/or a fusion partner, such as, albumin, Fc sequence, and the like.

Therapeutic and Prophylactic Uses

The present disclosure contemplates the use of the IL-10 agentsdescribed herein (e.g., PEG-IL-10) to prevent or reduce the severity ofactivation-induced cell death in patients undergoing CAR-T cell therapy.More specifically, IL-10 agents are used in methods directed to themodulation of a T cell-mediated immune response to a target cellpopulation in a subject, comprising introducing to the subject atherapeutically effective plurality of cells genetically modified toexpress a chimeric antigen receptor, wherein the chimeric antigenreceptor comprises at least one antigen-specific targeting regioncapable of binding to the target cell population, and wherein thebinding of the chimeric antigen receptor targeting region to the targetcell population is capable of eliciting activation-induced cell death.

In particular embodiments, a therapeutically effective amount of theIL-10 agent sufficient to prevent or limit the activation-induced celldeath is administered parenterally (e.g., subcutaneously) to thesubject. In other embodiments, a therapeutically effective plurality ofcells genetically modified to express a chimeric antigen receptor and anIL-10 agent in an amount sufficient to prevent or limit theactivation-induced cell death is introduced into the subject. In stillfurther embodiments, a therapeutically effective amount of the IL-10agent sufficient to prevent or limit the activation-induced cell deathis introduced into the subject by means of cells genetically modified toexpress the IL-10 agent, whereby the expression construct is present indifferent cells than those that express a CAR.

The genetic material encoding an IL-10 agent can be introduced intocells by any means known to the skilled artisan. The two major classesof methods are those that use recombinant viruses (also referred to asviral vectors) and those that use naked DNA or DNA complexes (non-viralmethods). Examples of viruses that may be used include, but are notlimited to, retroviruses, adenoviruses and herpes simplex virus.Examples of non-viral methods include, but are not limited to, injectionof naked DNA, physical methods to enhance delivery (e.g.,electroporation), and chemical methods to enhance delivery (e.g.,lipoplexes).

In certain embodiments of the present disclosure, a vector (e.g., aviral vector) is genetically engineered to deliver the gene. The vectorcan be given intravenously or injected directly into a specific tissuein the body, where it is taken up by individual cells. Alternately, aportion of the subject's cells can be removed and exposed to the vectorin an ex vivo setting, followed by the return of the cells containingthe vector to the patient. In particular embodiments, expression of theIL-10 agent is modulated by an expression control element.

The CAR-T cell therapy used in conjunction with an IL-10 agent describedherein can be used to treat or prevent a proliferative disease, disorderor condition, including a cancer, for example, cancer of the uterus,cervix, breast, prostate, testes, gastrointestinal tract (e.g.,esophagus, oropharynx, stomach, small or large intestines, colon, orrectum), kidney, renal cell, bladder, bone, bone marrow, skin, head orneck, liver, gall bladder, heart, lung, pancreas, salivary gland,adrenal gland, thyroid, brain (e.g., gliomas), ganglia, central nervoussystem (CNS) and peripheral nervous system (PNS), and cancers of thehematopoietic system and the immune system (e.g., spleen or thymus). Thepresent disclosure also provides methods of treating or preventing othercancer-related diseases, disorders or conditions, including, forexample, immunogenic tumors, non-immunogenic tumors, dormant tumors,virus-induced cancers (e.g., epithelial cell cancers, endothelial cellcancers, squamous cell carcinomas and papillomavirus), adenocarcinomas,lymphomas, carcinomas, melanomas, leukemias, myelomas, sarcomas,teratocarcinomas, chemically-induced cancers, metastasis, andangiogenesis. The disclosure contemplates reducing tolerance to a tumorcell or cancer cell antigen, e.g., by modulating activity of aregulatory T-cell and/or a CD8+ T-cell (see, e.g., Ramirez-Montagut, etal. (2003) Oncogene 22:3180-87; and Sawaya, et al. (2003) New Engl. J.Med. 349:1501-09). In particular embodiments, the tumor or cancer iscolon cancer, ovarian cancer, breast cancer, melanoma, lung cancer,glioblastoma, or leukemia. The use of the term(s) cancer-relateddiseases, disorders and conditions is meant to refer broadly toconditions that are associated, directly or indirectly, with cancer, andincludes, e.g., angiogenesis and precancerous conditions such asdysplasia.

In other embodiments, the CAR-T cell therapy used in conjunction with anIL-10 agent described herein can be used to treat or prevent animmune/inflammatory-related disorder. As used herein, terms such as“immune disease”, “immune condition”, “immune disorder”, “inflammatorydisease”, “inflammatory condition”, “inflammatory disorder” and the likeare meant to broadly encompass any immune- or inflammatory-relatedcondition (e.g., pathological inflammation and autoimmune diseases).Such conditions frequently are inextricably intertwined with otherdiseases, disorders and conditions. By way of example, an “immunecondition” may refer to proliferative conditions, such as cancer,tumors, and angiogenesis; including infections (acute and chronic),tumors, and cancers that resist eradication by the immune system.

A non-limiting list of immune- and inflammatory-related diseases,disorders and conditions includes arthritis (e.g., rheumatoidarthritis), kidney failure, lupus, asthma, psoriasis, colitis,pancreatitis, allergies, fibrosis, surgical complications (e.g., whereinflammatory cytokines prevent healing), anemia, and fibromyalgia. Otherdiseases and disorders which may be associated with chronic inflammationinclude Alzheimer's disease, congestive heart failure, stroke, aorticvalve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease,infections, inflammatory bowel disease (e.g., Crohn's disease andulcerative colitis), allergic contact dermatitis and other eczemas,systemic sclerosis, transplantation and multiple sclerosis.

Pharmaceutical Compositions

When an IL-10 agent is administered to a subject, the present disclosurecontemplates the use of any form of compositions suitable foradministration to the subject. In general, such compositions are“pharmaceutical compositions” comprising IL-10 and one or morepharmaceutically acceptable or physiologically acceptable diluents,carriers or excipients. The pharmaceutical compositions can be used inthe methods of the present disclosure; thus, for example, thepharmaceutical compositions can be administered ex vivo or in vivo to asubject in order to practice the therapeutic and prophylactic methodsand uses described herein.

The pharmaceutical compositions of the present disclosure can beformulated to be compatible with the intended method or route ofadministration; exemplary routes of administration are set forth herein.Furthermore, the pharmaceutical compositions can be used in combinationwith other therapeutically active agents or compounds as describedherein in order to treat or prevent the diseases, disorders andconditions as contemplated by the present disclosure.

The pharmaceutical compositions typically comprise a therapeuticallyeffective amount of an IL-10 agent contemplated by the presentdisclosure and one or more pharmaceutically and physiologicallyacceptable formulation agents. Suitable pharmaceutically acceptable orphysiologically acceptable diluents, carriers or excipients include, butare not limited to, antioxidants (e.g., ascorbic acid and sodiumbisulfate), preservatives (e.g., benzyl alcohol, methyl parabens, ethylor n-propyl, p-hydroxybenzoate), emulsifying agents, suspending agents,dispersing agents, solvents, fillers, bulking agents, detergents,buffers, vehicles, diluents, and/or adjuvants. For example, a suitablevehicle can be a physiological saline solution or citrate bufferedsaline, possibly supplemented with other materials common inpharmaceutical compositions for parenteral administration. Neutralbuffered saline or saline mixed with serum albumin are further exemplaryvehicles. Those skilled in the art will readily recognize a variety ofbuffers that can be used in the pharmaceutical compositions and dosageforms contemplated herein. Typical buffers include, but are not limitedto, pharmaceutically acceptable weak acids, weak bases, or mixturesthereof. As an example, the buffer components can be water solublematerials such as phosphoric acid, tartaric acids, lactic acid, succinicacid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamicacid, and salts thereof. Acceptable buffering agents include, forexample, a Tris buffer,N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES),2-(N-Morpholino)ethanesulfonic acid (MES),2-(N-Morpholino)ethanesulfonic acid sodium salt (MES),3-(N-Morpholino)propanesulfonic acid (MOPS), andN-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS).

After a pharmaceutical composition has been formulated, it can be storedin sterile vials as a solution, suspension, gel, emulsion, solid, ordehydrated or lyophilized powder. Such formulations can be stored eitherin a ready-to-use form, a lyophilized form requiring reconstitutionprior to use, a liquid form requiring dilution prior to use, or otheracceptable form. In some embodiments, the pharmaceutical composition isprovided in a single-use container (e.g., a single-use vial, ampoule,syringe, or autoinjector (similar to, e.g., an EpiPen®)), whereas amulti-use container (e.g., a multi-use vial) is provided in otherembodiments. Any drug delivery apparatus can be used to deliver IL-10,including implants (e.g., implantable pumps) and catheter systems, slowinjection pumps and devices, all of which are well known to the skilledartisan. Depot injections, which are generally administeredsubcutaneously or intramuscularly, can also be utilized to release thepolypeptides disclosed herein over a defined period of time. Depotinjections are usually either solid- or oil-based and generally compriseat least one of the formulation components set forth herein. One ofordinary skill in the art is familiar with possible formulations anduses of depot injections.

The pharmaceutical compositions can be in the form of a sterileinjectable aqueous or oleagenous suspension. This suspension can beformulated according to the known art using those suitable dispersing orwetting agents and suspending agents mentioned herein. The sterileinjectable preparation can also be a sterile injectable solution orsuspension in a non-toxic parenterally-acceptable diluent or solvent,for example, as a solution in 1,3-butane diol. Acceptable diluents,solvents and dispersion media that can be employed include water,Ringer's solution, isotonic sodium chloride solution, Cremophor EL™(BASF, Parsippany, N.J.) or phosphate buffered saline (PBS), ethanol,polyol (e.g., glycerol, propylene glycol, and liquid polyethyleneglycol), and suitable mixtures thereof. In addition, sterile, fixed oilsare conventionally employed as a solvent or suspending medium. For thispurpose any bland fixed oil can be employed, including synthetic mono-or diglycerides. Moreover, fatty acids such as oleic acid, find use inthe preparation of injectables. Prolonged absorption of particularinjectable formulations can be achieved by including an agent thatdelays absorption (e.g., aluminum monostearate or gelatin).

The pharmaceutical compositions containing the active ingredient can bein a form suitable for oral use, for example, as tablets, capsules,troches, lozenges, aqueous or oily suspensions, dispersible powders orgranules, emulsions, hard or soft capsules, or syrups, solutions,microbeads or elixirs. In particular embodiments, an active ingredientof an agent co-administered with an IL-10 agent described herein is in aform suitable for oral use. Pharmaceutical compositions intended fororal use can be prepared according to any method known to the art forthe manufacture of pharmaceutical compositions, and such compositionscan contain one or more agents such as, for example, sweetening agents,flavoring agents, coloring agents and preserving agents in order toprovide pharmaceutically elegant and palatable preparations. Tablets,capsules and the like contain the active ingredient in admixture withnon-toxic pharmaceutically acceptable excipients which are suitable forthe manufacture of tablets. These excipients can be, for example,diluents, such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for examplestarch, gelatin or acacia, and lubricating agents, for example magnesiumstearate, stearic acid or talc.

The tablets, capsules and the like suitable for oral administration canbe uncoated or coated by known techniques to delay disintegration andabsorption in the gastrointestinal tract and thereby provide a sustainedaction. For example, a time-delay material such as glyceryl monostearateor glyceryl distearate can be employed. They can also be coated bytechniques known in the art to form osmotic therapeutic tablets forcontrolled release. Additional agents include biodegradable orbiocompatible particles or a polymeric substance such as polyesters,polyamine acids, hydrogel, polyvinyl pyrrolidone, polyanhydrides,polyglycolic acid, ethylene-vinylacetate, methylcellulose,carboxymethylcellulose, protamine sulfate, orlactide/glycolidecopolymers, polylactide/glycolide copolymers, or ethylenevinylacetatecopolymers in order to control delivery of an administered composition.For example, the oral agent can be entrapped in microcapsules preparedby coacervation techniques or by interfacial polymerization, by the useof hydroxymethylcellulose or gelatin-microcapsules or poly(methylmethacrolate) microcapsules, respectively, or in a colloid drugdelivery system. Colloidal dispersion systems include macromoleculecomplexes, nano-capsules, microspheres, microbeads, and lipid-basedsystems, including oil-in-water emulsions, micelles, mixed micelles, andliposomes. Methods for the preparation of the above-mentionedformulations will be apparent to those skilled in the art.

Formulations for oral use can also be presented as hard gelatin capsuleswherein the active ingredient is mixed with an inert solid diluent, forexample, calcium carbonate, calcium phosphate, kaolin ormicrocrystalline cellulose, or as soft gelatin capsules wherein theactive ingredient is mixed with water or an oil medium, for examplepeanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active materials in admixture withexcipients suitable for the manufacture thereof. Such excipients can besuspending agents, for example sodium carboxymethylcellulose,methylcellulose, hydroxy-propylmethylcellulose, sodium alginate,polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing orwetting agents, for example a naturally-occurring phosphatide (e.g.,lecithin), or condensation products of an alkylene oxide with fattyacids (e.g., polyoxy-ethylene stearate), or condensation products ofethylene oxide with long chain aliphatic alcohols (e.g., forheptadecaethyleneoxycetanol), or condensation products of ethylene oxidewith partial esters derived from fatty acids and a hexitol (e.g.,polyoxyethylene sorbitol monooleate), or condensation products ofethylene oxide with partial esters derived from fatty acids and hexitolanhydrides (e.g., polyethylene sorbitan monooleate). The aqueoussuspensions can also contain one or more preservatives.

Oily suspensions can be formulated by suspending the active ingredientin a vegetable oil, for example arachis oil, olive oil, sesame oil orcoconut oil, or in a mineral oil such as liquid paraffin. The oilysuspensions can contain a thickening agent, for example beeswax, hardparaffin or cetyl alcohol. Sweetening agents such as those set forthabove, and flavoring agents can be added to provide a palatable oralpreparation.

Dispersible powders and granules suitable for preparation of an aqueoussuspension by the addition of water provide the active ingredient inadmixture with a dispersing or wetting agent, suspending agent and oneor more preservatives. Suitable dispersing or wetting agents andsuspending agents are exemplified herein.

The pharmaceutical compositions of the present disclosure can also be inthe form of oil-in-water emulsions. The oily phase can be a vegetableoil, for example olive oil or arachis oil, or a mineral oil, forexample, liquid paraffin, or mixtures of these. Suitable emulsifyingagents can be naturally occurring gums, for example, gum acacia or gumtragacanth; naturally occurring phosphatides, for example, soy bean,lecithin, and esters or partial esters derived from fatty acids; hexitolanhydrides, for example, sorbitan monooleate; and condensation productsof partial esters with ethylene oxide, for example, polyoxyethylenesorbitan monooleate.

Formulations can also include carriers to protect the compositionagainst rapid degradation or elimination from the body, such as acontrolled release formulation, including implants, liposomes,hydrogels, prodrugs and microencapsulated delivery systems. For example,a time delay material such as glyceryl monostearate or glyceryl stearatealone, or in combination with a wax, can be employed.

The present disclosure contemplates the administration of the IL-10polypeptides in the form of suppositories for rectal administration. Thesuppositories can be prepared by mixing the drug with a suitablenon-irritating excipient which is solid at ordinary temperatures butliquid at the rectal temperature and will therefore melt in the rectumto release the drug. Such materials include, but are not limited to,cocoa butter and polyethylene glycols.

The IL-10 agents (e.g., PEG-IL-10) and other agents contemplated by thepresent disclosure can be in the form of any other suitablepharmaceutical composition (e.g., sprays for nasal or inhalation use)currently known or developed in the future.

The concentration of a polypeptide (e.g., IL-10) or fragment thereof ina formulation can vary widely (e.g., from less than about 0.1%, usuallyat or at least about 2% to as much as 20% to 50% or more by weight) andwill usually be selected primarily based on fluid volumes, viscosities,and subject-based factors in accordance with, for example, theparticular mode of administration selected.

Routes of Administration

The present disclosure contemplates the administration of the IL-10agent (e.g., PEG-IL-10), and compositions thereof, in any appropriatemanner. Suitable routes of administration include parenteral (e.g.,intramuscular, intravenous, subcutaneous (e.g., injection or implant),intraperitoneal, intracisternal, intraarticular, intraperitoneal,intracerebral (intraparenchymal) and intracerebroventricular), oral,nasal, vaginal, sublingual, intraocular, rectal, topical (e.g.,transdermal), sublingual and inhalation. Depot injections, which aregenerally administered subcutaneously or intramuscularly, can also beutilized to release the IL-10 agents disclosed herein over a definedperiod of time.

In some particular embodiments of the present disclosure, the IL-10agents (e.g., PEG-IL-10) are administered parenterally, and in furtherparticular embodiments the parenteral administration is subcutaneous.

As to the CAR-T cell therapy, described herein are alternative means forintroducing to a subject a therapeutically effective plurality of cellsgenetically modified to express a chimeric antigen receptor, wherein thechimeric antigen receptor comprises at least one antigen-specifictargeting region capable of binding to the target cell population, andwherein the binding of the chimeric antigen receptor targeting region tothe target cell population is capable of eliciting activation-inducedcell death.

Combination Therapy

In conjunction with the CAR-T T cell therapy described herein, thepresent disclosure contemplates the use of an IL-10 agent (e.g.,PEG-IL-10) in combination with one or more active agents (e.g.,chemotherapeutic agents) or other prophylactic or therapeuticnon-pharmacological modalities (e.g., localized radiation therapy ortotal body radiation therapy). By way of example, the present disclosurecontemplates treatment regimens wherein a radiation phase is preceded orfollowed by treatment with one or more additional therapies (e.g., CAR-TT cell therapy and administration of an IL-10 agent) or agents asdescribed herein. In some embodiments, the present disclosure furthercontemplates the use of CAR-T T cell therapy and an IL-10 agent (e.g.,PEG-IL-10) in combination with bone marrow transplantation, peripheralblood stem cell transplantation, or other types of transplantationtherapy.

As used herein, “combination therapy” is meant to include therapies thatcan be administered or introduced separately, for example, formulatedseparately for separate administration (e.g., as may be provided in akit), and therapies that can be administered or introduced together. Incertain embodiments, the IL-10 agent and the other agent(s) areadministered or applied sequentially, e.g., where one agent isadministered prior to one or more other agents. In other embodiments,the IL-10 agent and the other agent(s) are administered simultaneously,e.g., where two or more agents are administered at or about the sametime; the two or more agents may be present in two or more separateformulations or combined into a single formulation (i.e., aco-formulation). Regardless of whether the agents are administeredsequentially or simultaneously, they are considered to be administeredin combination for purposes of the present disclosure.

The IL-10 agents of the present disclosure may be used in combinationwith at least one other active agent in any manner appropriate under thecircumstances. In one embodiment, treatment with the IL-10 agent and theother agent(s) is maintained over a period of time. In anotherembodiment, treatment with the at least one other agent(s) is reduced ordiscontinued (e.g., when the subject is stable), while treatment with anIL-10 agent of the present disclosure (e.g., PEG-IL-10) is maintained ata constant dosing regimen. In a further embodiment, treatment with theother agent(s) is reduced or discontinued (e.g., when the subject isstable), while treatment with an IL-10 agent of the present disclosureis reduced (e.g., lower dose, less frequent dosing or shorter treatmentregimen). In yet another embodiment, treatment with the other agent(s)is reduced or discontinued (e.g., when the subject is stable), andtreatment with the IL-10 agent of the present disclosure is increased(e.g., higher dose, more frequent dosing or longer treatment regimen).In yet another embodiment, treatment with the other agent(s) ismaintained and treatment with the IL-10 agent of the present disclosureis reduced or discontinued (e.g., lower dose, less frequent dosing orshorter treatment regimen). In yet another embodiment, treatment withthe other agent(s) and treatment with an IL-10 agent of the presentdisclosure (e.g., PEG-IL-10) are reduced or discontinued (e.g., lowerdose, less frequent dosing or shorter treatment regimen).

In conjunction with the CAR-T T cell therapy described herein, thepresent disclosure provides methods for treating and/or preventing aproliferative condition, cancer, tumor, or precancerous disease,disorder or condition with an IL-10 agent (e.g., PEG-IL-10) and at leastone additional therapeutic or prophylactic agent(s) or diagnostic agentexhibiting a desired activity. Some embodiments of the presentdisclosure contemplate the use of traditional chemotherapeutic agents(e.g., alkylating agents, nitrogen mustards, nitrosureas, antibiotics,anti-metabolites, folic acid analogs, purine analogs, pyrimidineanalogs, antihormonal agents and taxoids). Other embodiments of thepresent disclosure contemplate methods for tumor suppression or tumorgrowth comprising administration of an IL-10 agent described herein incombination with a signal transduction inhibitor (e.g., GLEEVEC orHERCEPTIN) or an immunomodulator to achieve additive or synergisticsuppression of tumor growth.

In conjunction with the CAR-T T cell therapy described herein, thepresent disclosure also provides methods for treating and/or preventingimmune- and/or inflammatory-related diseases, disorders and conditions,as well as disorders associated therewith, with an IL-10 agent (e.g.,PEG-IL-10) and at least one additional agent(s) or diagnostic agentexhibiting a desired activity. Examples of therapeutic agents useful incombination therapy include, but are not limited to non-steroidalanti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors,steroids, TNF antagonists (e.g., REMICADE and ENBREL), interferon-β1a(AVONEX), interferon-β1b (BETASERON), and immune checkpoint inhibitors(e.g., YERVOY).

Dosing

The IL-10 agents (e.g., PEG-IL-10) of the present disclosure can beadministered to a subject in an amount that is dependent upon, forexample, the goal of the administration (e.g., the degree of resolutiondesired); the age, weight, sex, and health and physical condition of thesubject the formulation being administered; and the route ofadministration. Effective dosage amounts and dosage regimens can readilybe determined from, for example, safety and dose-escalation trials, invivo studies (e.g., animal models), and other methods known to theskilled artisan.

As discussed in detail elsewhere, the present disclosure contemplatesembodiments wherein administration of IL-10 to achieve certain serumtrough concentrations and/or maintain certain mean serum troughconcentrations.

In general, dosing parameters dictate that the dosage amount be lessthan an amount that could be irreversibly toxic to the subject (i.e.,the maximum tolerated dose, “MTD”) and not less than an amount requiredto produce a measurable effect on the subject. Such amounts aredetermined by, for example, the pharmacokinetic and pharmacodynamicparameters associated with ADME, taking into consideration the route ofadministration and other factors.

An effective dose (ED) is the dose or amount of an agent that produces atherapeutic response or desired effect in some fraction of the subjectstaking it. The “median effective dose” or ED50 of an agent is the doseor amount of an agent that produces a therapeutic response or desiredeffect in 50% of the population to which it is administered. Althoughthe ED50 is commonly used as a measure of reasonable expectance of anagent's effect, it is not necessarily the dose that a clinician mightdeem appropriate taking into consideration all relevant factors. Thus,in some situations the effective amount can be more than the calculatedED50, in other situations the effective amount can be less than thecalculated ED50, and in still other situations the effective amount canbe the same as the calculated ED50.

The therapeutically effective amount of PEG-IL-10 can range from about0.01 to about 100 μg protein/kg of body weight/day, from about 0.1 to 20μg protein/kg of body weight/day, from about 0.5 to 10 μg protein/kg ofbody weight/day, or about 1 to 4 μg protein/kg of body weight/day. Insome embodiments, PEG-IL-10 is administered by continuous infusion todelivery about 50 to 800 μg protein/kg of body weight/day (e.g., about 1to 16 μg protein/kg of body weight/day of PEG-IL-10). The infusion ratecan be varied based on evaluation of, for example, adverse effects andblood cell counts. Other specific dosing parameters for the IL-10 agentsare described elsewhere herein.

In certain embodiments, the dosage of the disclosed IL-10 agent iscontained in a “unit dosage form”. The phrase “unit dosage form” refersto physically discrete units, each unit containing a predeterminedamount of the IL-10 agent of the present disclosure, either alone or incombination with one or more additional agents, sufficient to producethe desired effect. It will be appreciated that the parameters of a unitdosage form will depend on the particular agent and the effect to beachieved.

Kits

The present disclosure also contemplates kits comprising an IL-10 agent(e.g., PEG-IL-10), and a pharmaceutical composition thereof. The kitsare generally in the form of a physical structure housing variouscomponents, as described below, and can be utilized, for example, inpracticing the methods described above.

A kit can include an IL-10 agent (e.g., PEG-IL-10) disclosed herein(provided in, e.g., a sterile container), which can be in the form of apharmaceutical composition suitable for administration to a subject. TheIL-10 agent can be provided in a form that is ready for use or in a formrequiring, for example, reconstitution or dilution prior toadministration. When the IL-10 agent is in a form that needs to bereconstituted by a user, the kit can also include buffers,pharmaceutically acceptable excipients, and the like, packaged with orseparately from the IL-10 agent. A kit can also contain both the IL-10agent and/or components of the specific CAR-T T cell therapy to be used;the kit can contain the several agents separately or they can already becombined in the kit. A kit of the present disclosure can be designed forconditions necessary to properly maintain the components housed therein(e.g., refrigeration or freezing).

A kit can contain a label or packaging insert including identifyinginformation for the components therein and instructions for their use(e.g., dosing parameters, clinical pharmacology of the activeingredient(s), including mechanism(s) of action, pharmacokinetics andpharmacodynamics, adverse effects, contraindications, etc.). Eachcomponent of the kit can be enclosed within an individual container, andall of the various containers can be within a single package. Labels orinserts can include manufacturer information such as lot numbers andexpiration dates. The label or packaging insert can be, e.g., integratedinto the physical structure housing the components, contained separatelywithin the physical structure, or affixed to a component of the kit(e.g., an ampule, syringe or vial).

Labels or inserts can additionally include, or be incorporated into, acomputer readable medium, such as a disk (e.g., hard disk, card, memorydisk), optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape,or an electrical storage media such as RAM and ROM or hybrids of thesesuch as magnetic/optical storage media, FLASH media or memory-typecards. In some embodiments, the actual instructions are not present inthe kit, but means for obtaining the instructions from a remote source,e.g., via an internet site, are provided.

EXPERIMENTAL

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how tomake and use the present invention, and are not intended to limit thescope of what the inventors regard as their invention nor are theyintended to represent that the experiments below were performed and areall of the experiments that can be performed. It is to be understoodthat exemplary descriptions written in the present tense were notnecessarily performed, but rather that the descriptions can be performedto generate the data and the like described therein. Efforts have beenmade to ensure accuracy with respect to numbers used (e.g., amounts,temperature, etc.), but some experimental errors and deviations shouldbe accounted for.

Unless indicated otherwise, parts are parts by weight, molecular weightis weight average molecular weight, temperature is in degrees Celsius (°C.), and pressure is at or near atmospheric. Standard abbreviations areused, including the following: s or sec=second(s); min=minute(s); h orhr=hour(s); aa=amino acid(s); bp=base pair(s); kb=kilobase(s);nt=nucleotide(s); ng=nanogram; μg=microgram; mg=milligram; g=gram;kg=kilogram; dl or dL=deciliter; μl or μL=microliter; ml ormL=milliliter; l or L=liter; nM=nanomolar; μM=micromolar; mM=millimolar;M=molar; kDa=kilodalton; i.m.=intramuscular(ly);i.p.=intraperitoneal(ly); SC or SQ=subcutaneous(ly); HPLC=highperformance liquid chromatography; BW=body weight; U=unit; ns=notstatistically significant; PMA=Phorbol 12-myristate 13-acetate;PBS=phosphate-buffered saline; DMEM=Dulbeco's Modification of Eagle'sMedium; PBMCs=primary peripheral blood mononuclear cells; FBS=fetalbovine serum; FCS=fetal calf serum;HEPES=4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;LPS=lipopolysaccharide; RPMI=Roswell Park Memorial Institute medium;APC=antigen presenting cells; FACS=fluorescence-activated cell sorting.

Materials and Methods.

The following general materials and methods were used, where indicated,or may be used in the Examples below:

Molecular Biology Procedures.

Standard methods in molecular biology are described in the scientificliterature (see, e.g., Sambrook and Russell (2001) Molecular Cloning,3^(rd) ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor,N.Y.; and Ausubel, et al. (2001) Current Protocols in Molecular Biology,Vols. 1-4, John Wiley and Sons, Inc. New York, N.Y., which describescloning in bacterial cells and DNA mutagenesis (Vol. 1), cloning inmammalian cells and yeast (Vol. 2), glycoconjugates and proteinexpression (Vol. 3), and bioinformatics (Vol. 4)).

Antibody-Related Processes.

Production, purification, and fragmentation of polyclonal and monoclonalantibodies are described (e.g., Harlow and Lane (1999) Using Antibodies,Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); standardtechniques for characterizing ligand/receptor interactions are available(see, e.g., Coligan et al. (2001) Current Protocols in Immunology, Vol.4, John Wiley, Inc., NY); methods for flow cytometry, includingfluorescence-activated cell sorting (FACS), are available (see, e.g.,Shapiro (2003) Practical Flow Cytometry, John Wiley and Sons, Hoboken,N.J.); and fluorescent reagents suitable for modifying nucleic acids,including nucleic acid primers and probes, polypeptides, and antibodies,for use, e.g., as diagnostic reagents, are available (Molecular Probes(2003) Catalogue, Molecular Probes, Inc., Eugene, Oreg.; Sigma-Aldrich(2003) Catalogue, St. Louis, Mo.). Further discussion of antibodiesappears elsewhere herein.

Software.

Software packages and databases for determining, e.g., antigenicfragments, leader sequences, protein folding, functional domains,glycosylation sites, and sequence alignments, are available (see, e.g.,GCG Wisconsin Package (Accelrys, Inc., San Diego, Calif.); and DeCypher™(TimeLogic Corp., Crystal Bay, Nev.).

Pegylation.

Pegylated IL-10 as described herein may be synthesized by any meansknown to the skilled artisan. Exemplary synthetic schemes for producingmono-PEG-IL-10 and a mix of mono-/di-PEG-IL-10 have been described (see,e.g., U.S. Pat. No. 7,052,686; US Pat. Publn. No. 2011/0250163; WO2010/077853). Particular embodiments of the present disclosure comprisea mix of selectively pegylated mono- and di-PEG-IL-10. In addition toleveraging her own skills in the production and use of PEGs (and otherdrug delivery technologies) suitable in the practice of the presentdisclosure, the skilled artisan is familiar with many commercialsuppliers of PEG-related technologies (e.g., NOF America Corp (Irvine,Calif.) and Parchem (New Rochelle, N.Y.)).

Animals.

Various mice and other animal strains known to the skilled artisan canbe used in conjunction with the teachings of the present disclosure. Forexample, immunocompetent Balb/C or B-cell—deficient Balb/C mice can beobtained from The Jackson Lab., Bar Harbor, Me. and used in accordancewith standard procedures (see, e.g., Martin et al (2001) Infect. Immun.,69(11):7067-73 and Compton et al. (2004) Comp. Med. 54(6):681-89).

IL-10 Concentrations.

Serum IL-10 concentration levels and exposure levels can be determinedby standard methods used in the art. For example, when the experimentalsubject is a mouse, a serum exposure level assay can be performed bycollecting whole blood (˜50 μL/mouse) from mouse tail snips into plaincapillary tubes, separating serum and blood cells by centrifugation, anddetermining IL-10 exposure levels by standard ELISA kits and techniques.

FACS Analysis.

Numerous protocols, materials and reagents for FACS analysis arecommercially available and may be used in conjunction with the teachingsherein (e.g., Becton-Dickinson, Franklin Lakes, N.J.; Cell SignalingTechnologies, Danford, Mass.; Abcam, Cambridge, Mass.; Affymetrix, SantaClara, Calif.). Both direct flow cytometry (i.e., using a conjugatedprimary antibody) and indirect flow cytometry (i.e., using a primaryantibody and conjugated secondary antibody) may be used. An exemplarydirect flow protocol is as follows: Wash harvested cells and adjust cellsuspension to a concentration of 1-5×10⁶ cells/mL in ice-cold PBS, 10%FCS, 1% sodium azide. Cells may be stained in polystyrene round bottom12×75 mm² Falcon tubes. Cells may be centrifuged sufficiently so thesupernatant fluid may be removed with little loss of cells, but not tothe extent that the cells are difficult to resuspend. The primarylabeled antibody may be added (0.1-10 μm/mL), and dilutions, ifnecessary, may be made in 3% BSA/PBS. After incubation for at least 30min at 4° C., cells may be washed 3× by centrifugation at 400 g for 5min and then may be resuspended in 0.5-1 mL of ice-cold PBS, 10% FCS, 1%sodium azide. Cells may be maintained in the dark on ice until analysis(preferably within the same day). Cells may also be fixed, usingstandard methodologies, to preserve them for several days; fixation fordifferent antigens may require antigen-specific optimization.

The assays described hereafter are representative, and not exclusionary.

PBMC and CD8+ T-Cell Gene Expression Assay.

The following protocol provides an exemplary assay to examine geneexpression.

Human PBMCs can be isolated according to any standard protocol (see,e.g., Fuss et al. (2009) Current Protocols in Immunology, Unit 7.1, JohnWiley, Inc., NY). 2.5 mL of PBMCs (at a cell density of 8 millioncells/mL) can be cultured per well with complete RPMI, containing RPMI(Life Technologies; Carlsbad, Calif.), 10 mM HEPES (Life Technologies;Carlsbad, Calif.), 10% FCS (Hyclone Thermo Fisher Scientific; Waltham,Mass.) and Penicillin/Streptomycin cocktail (Life Technologies;Carlsbad, Calif.), in any standard tissue culture treated 6-well plate(BD; Franklin Lakes, N.J.). Human pegylated-IL-10 can be added to thewells at a final concentration of 100 ng/mL, followed by a 7-dayincubation. CD8+ T-cells can be isolated from the PBMCs using MiltenyiBiotec's MACS cell separation technology according to the manufacturer'sprotocol (Miltenyi Biotec; Auburn, Calif.). RNA can be extracted andcDNA can be synthesized from the isolated CD8+ T-cells and the CD8+T-cell depleted-PBMCs using Qiagen's RNeasy Kit and RT² First StrandKit, respectively, following the manufacturer's instructions (QiagenN.V.; Netherlands). Quantitative PCR can be performed on the cDNAtemplate using the RT² SYBR Green qPCR Mastermix and primers (IDO1,GUSB, and GAPDH) from Qiagen according to the manufacturer's protocol.IDO1 Ct values can be normalized to the average Ct value of thehousekeeping genes, GUSB and GAPDH.

PBMC and CD8+ T-cell Cytokine Secretion Assay.

Activated primary human CD8+ T-cells secrete IFN-γ when treated withPEG-IL-10 and then with an anti-CD3 antibody. The following protocolprovides an exemplary assay to examine cytokine secretion.

Human PBMCs can be isolated according to any standard protocol (see,e.g., Fuss et al. (2009) Current Protocols in Immunology, Unit 7.1, JohnWiley, Inc., NY). 2.5 mL of PBMCs (at a cell density of 8 millioncells/mL) can be cultured per well with complete RPMI, containing RPMI(Life Technologies; Carlsbad, Calif.), 10 mM HEPES (Life Technologies;Carlsbad, Calif.), 10% FCS (Hyclone Thermo Fisher Scientific; Waltham,Mass.) and Penicillin/Streptomycin cocktail (Life Technologies;Carlsbad, Calif.), in any standard tissue culture treated 6-well plate(BD; Franklin Lakes, N.J.). Human pegylated-IL-10 can be added to thewells at a final concentration of 100 ng/mL, followed by a 3-dayincubation. CD8+ T-cells can be isolated from the PBMCs using MiltenyiBiotec's MACS cell separation technology according to the manufacture'sprotocol (Miltenyi Biotec; Auburn, Calif.). The isolated CD8+ T-cellscan then be cultured with complete RPMI containing 1 μg/mL anti-CD3antibody (Affymetrix eBioscience) in any standard tissue culture platefor 4 hours. After the 4-hour incubation, the media can be collected andassayed for IFN-γ using a commercial ELISA kit and following themanufacture's protocol (Affymetrix eBioscience).

TNFα Inhibition Assay.

PMA-stimulation of U937 cells (lymphoblast human cell line from lungavailable from Sigma-Aldrich (#85011440); St. Louis, Mo.) causes thecells to secrete TNFα, and subsequent treatment of these TNFα-secretingcells with human IL-10 causes a decrease in TNFα secretion in adose-dependent manner. An exemplary TNFα inhibition assay can beperformed using the following protocol.

After culturing U937 cells in RMPI containing 10% FBS/FCS andantibiotics, plate 1×105, 90% viable U937 cells in 96-well flat bottomplates (any plasma-treated tissue culture plates (e.g., Nunc; ThermoScientific, USA) can be used) in triplicate per condition. Plate cellsto provide for the following conditions (all in at least triplicate; for‘media alone’ the number of wells is doubled because one-half will beused for viability after incubation with 10 nM PMA): 5 ng/mL LPS alone;5 ng/mL LPS+0.1 ng/mL rhIL-10; 5 ng/mL LPS+1 ng/mL rhIL-10; 5 ng/mLLPS+10 ng/mL rhIL-10; 5 ng/mL LPS+100 ng/mL rhIL-10; 5 ng/mL LPS+1000ng/mL rhIL-10; 5 ng/mL LPS+0.1 ng/mL PEG-rhIL-10; 5 ng/mL LPS+1 ng/mLPEG-rhIL-10; 5 ng/mL LPS+10 ng/mL PEG-rhIL-10; 5 ng/mL LPS+100 ng/mLPEG-rhIL-10; and 5 ng/mL LPS+1000 ng/mL PEG-rhIL-10. Expose each well to10 nM PMA in 200 μL for 24 hours, culturing at 37° C. in 5% CO₂incubator, after which time ˜90% of cells should be adherent. The threeextra wells can be re-suspended, and the cells are counted to assessviability (>90% should be viable). Wash gently but thoroughly 3× withfresh, non-PMA—containing media, ensuring that cells are still in thewells. Add 100 μL per well of media containing the appropriateconcentrations (2× as the volume will be diluted by 100%) of rhIL-10 orPEG-rhIL-10, incubate at 37° C. in a 5% CO₂ incubator for 30 minutes.Add 100 μL per well of 10 ng/mL stock LPS to achieve a finalconcentration of 5 ng/mL LPS in each well, and incubate at 37° C. in a5% CO₂ incubator for 18-24 hours. Remove supernatant and perform TNFαELISA according to the manufacturer's instructions. Run each conditionedsupernatant in duplicate in ELISA.

MC/9 Cell Proliferation Assay.

IL-10 administration to MC/9 cells (murine cell line withcharacteristics of mast cells available from Cell Signaling Technology;Danvers, Mass.) causes increased cell proliferation in a dose-dependentmanner. Thompson-Snipes, L. et al. (1991) J. Exp. Med. 173:507-10)describe a standard assay protocol in which MC/9 cells are supplementedwith IL3+IL-10 and IL-3+IL-4+IL-10. Vendors (e.g., R&D Systems, USA; andCell Signaling Technology, Danvers, Mass.) use the assay as a lotrelease assay for rhIL-10. Those of ordinary skill in the art will beable to modify the standard assay protocol described in Thompson-Snipes,L. et al, such that cells are only supplemented with IL-10.

Activation-Induced Cell Death Assay.

The following protocol provides an exemplary activation-induced celldeath assay.

Human PBMCs can be isolated according to any standard protocol (see,e.g., Fuss et al. (2009) Current Protocols in Immunology, Unit 7.1, JohnWiley, Inc., NY). CD8+T cells (CD45RO+) can be isolated using MiltenyiBiotec's anti-CD45R0 MACS beads and MACS cell separation technologyaccording to the manufacture's protocol (Miltenyi Biotec Inc; Auburn,Calif.). To activate cells, 1 mL of isolated cells (density of 3×10⁶cells/mL) can be cultured in AIM V media for 3 days (Life Technologies;Carlsbad, Calif.) in a standard 24-well plate (BD; Franklin Lakes, N.J.)pre-coated with anti-CD3 and anti-CD28 antibodies (AffymetrixeBioscience, San Diego, Calif.). The pre-coating process can be carriedout by adding 300 μL of carbonate buffer (0.1 M NaHCO₃(Sigma-Aldrich,St. Louis, Mo.), 0.5 M NaCl (Sigma-Aldrich), pH 8.3) containing 10 μg/mLanti-CD3 and 2 μg/mL anti-CD28 antibodies to each well, incubating for 2hours at 37° C., and washing each well with AIM V media. Following the3-day activation period, cells can be collected, counted, re-plated in 1mL of AIM V media (density of 2×10⁶ cells/mL) in a standard 24-wellplate and treated with 100 ng/mL PEG-hIL-10 for 3 days. The process ofactivation and treatment with PEG-hIL-10 can be repeated, after whichviable cells can be counted by Trypan Blue exclusion according to themanufacturer's protocol (Life Technologies).

Tumor Models and Tumor Analysis.

Any art-accepted tumor model, assay, and the like can be used toevaluate the effect of the IL-10 agents described herein on varioustumors. The tumor models and tumor analyses described hereafter arerepresentative of those that can be utilized. Syngeneic mouse tumorcells are injected subcutaneously or intradermally at 10⁴, 10⁵ or 10⁶cells per tumor inoculation. Ep2 mammary carcinoma, CT26 coloncarcinoma, PDV6 squamous carcinoma of the skin and 4T1 breast carcinomamodels can be used (see, e.g., Langowski et al. (2006) Nature442:461-465). Immunocompetent Balb/C or B-cell deficient Balb/C mice canbe used. PEG 10-mIL-10 can be administered to the immunocompetent mice,while PEG-hIL-10 treatment can be in the B-cell deficient mice. Tumorsare allowed to reach a size of 100-250 mm³ before treatment is started.IL-10, PEG-mIL-10, PEG-hIL-10, or buffer control is administered SC at asite distant from the tumor implantation. Tumor growth is typicallymonitored twice weekly using electronic calipers. Tumor tissues andlymphatic organs are harvested at various endpoints to measure mRNAexpression for a number of inflammatory markers and to performimmunohistochemistry for several inflammatory cell markers. The tissuesare snap-frozen in liquid nitrogen and stored at −80° C. Primary tumorgrowth is typically monitored twice weekly using electronic calipers.Tumor volume can be calculated using the formula (width²×length/2) wherelength is the longer dimension. Tumors are allowed to reach a size of90-250 mm³ before treatment is started.

Example 1 PEG-IL-10 Mediates CD8+ T Cell Immune Activation

The change in the number of PD-1- and LAG3-expressing CD8+ T cells wasdetermined in cancer patients before and after 29 days of treatment withPEG-rHuIL-10. Two patients who responded to the therapy with a sustainedpartial response had an increase of the PD1+CD8 T cells in the blood.The first patient (renal cell carcinoma) received 20 μg/kg PEG-rHuIL-10SC daily and experienced a 71% reduction of total tumor burden after 22weeks. The second patient (melanoma) received 40 μg/kg PEG-rHuIL-10 SCdaily and experienced a 57% reduction of total tumor burden after 22weeks.

Peripheral blood monocytic cells (PBMC) were isolated from the peripheryof each patient pre-treatment and during the treatment period and weresubjected to FACS analysis. As indicated in FIG. 1, the number ofperipheral CD8+ T cells expressing PD-1 increased by ˜2-fold within 29days and continued to increase during the treatment period., and thenumber of peripheral CD8+ T cells expressing LAG3 increased by ˜4-foldwithin 29 days. Both PD-1 and LAG3 are markers of CD8+ T cell activationand cytotoxic function. These findings suggest that PEG-rHuIL-10administration mediated CD8+ T cell immune activation.

Example 2 PEG-IL-10 Enhances the Function of Activated Memory CD8+ TCells

Memory T cells (also referred to as antigen-experienced T cells) are asubset of T lymphocytes (e.g., helper T cells (CD4+) and cytotoxic Tcells (CD8+)) that have previously encountered and responded to theircognate antigen during prior infection, exposure to cancer, or previousvaccination. In contrast, naïve T cells have not encountered theircognate antigen within the periphery; they are commonly characterized bythe absence of the activation markers CD25, CD44 or CD69, and theabsence of memory CD45RO isoform. Memory T cells, which are generallyCD45RO+, are able to reproduce and mount a faster and stronger immuneresponse than naïve T cells.

Given that CAR-T T cells are derived from memory CD8+ T cells, theeffect of PEG-IL-10 on memory CD8+ T cells was assessed in vitro usingstandard methodology, an example of which is described herein. Asindicated in FIG. 2, PEG-IL-10 preferentially enhances IFNγ productionin memory CD8+ T cells (CD45RO+) and not naïve CD8+ T cells. These dataare consistent with the effect of PEG-IL-10 to enhance the function ofactivated memory CD8+ T cells.

Example 3 PEG-IL-10 Treatment Results in a Greater Number of ActivatedMemory CD8+ T Cells

As described herein, CAR-T cell therapy is derived from memory CD8+ Tcells. In order to be effective, infused memory CD8+ T cells must notonly exhibit cytotoxicity, but must also persist (Curran K J, BrentjensR J. (20 Apr. 2015) J Clin Oncol pii: JCO.2014.60.3449; Berger et al.,(January 2008) J Clin Invest 118(1):294-305). However, repeatedactivation of T cells leads to activation-induced cell death, whichdecreases the number of cells and thus the overall therapeutic efficacy.

Using the procedure described herein, the activation-induced cell deathof human CD45RO+ memory CD8+ T cells from two donors was determined withand without treatment with PEG-IL-10. As indicated in FIG. 3, treatmentof human CD45RO+ memory CD8+ T cells with PEG-IL-10 after two rounds ofTCR and co-stimulation—induced activation resulted in a greater numberof viable cells. These data indicate that PEG-IL-10 is capable oflimiting activation-induced cell death, thus resulting in a greaternumber of activated memory T cells to persist. These observationssuggest that the use of PEG-IL-10 in combination with CAR-T cell therapyprovides additional clinical benefit.

Particular embodiments of this invention are described herein, includingthe best mode known to the inventors for carrying out the invention.Upon reading the foregoing, description, variations of the disclosedembodiments may become apparent to individuals working in the art, andit is expected that those skilled artisans may employ such variations asappropriate. Accordingly, it is intended that the invention be practicedotherwise than as specifically described herein, and that the inventionincludes all modifications and equivalents of the subject matter recitedin the claims appended hereto as permitted by applicable law. Moreover,any combination of the above-described elements in all possiblevariations thereof is encompassed by the invention unless otherwiseindicated herein or otherwise clearly contradicted by context.

All publications, patent applications, accession numbers, and otherreferences cited in this specification are herein incorporated byreference as if each individual publication or patent application werespecifically and individually indicated to be incorporated by reference.

1-123. (canceled)
 124. A genetically modified T-cell transformed with afirst nucleic acid sequence encoding a chimeric antigen receptor (CAR),wherein the CAR comprises: a) at least one antigen-specific targetingregion that specifically binds a cell surface antigen present on thetarget cell population, b) a transmembrane domain, and c) anintracellular signaling domain, and a second nucleic acid sequence,wherein the second nucleic acid sequence comprises: a) a nucleic acidencoding a signal peptide (SP); and b) a nucleic acid encoding an IL-10polypeptide the nucleic acid encoding the signal peptide being in framewith the nucleic acid sequence encoding the IL-10 polypeptide; whereinsaid first and second nucleic acid sequences are operably linked to atleast one transcriptional and translational regulatory sequence capableof directing the transcription and translation of a nucleic acidsequence in the genetically modified T-cell, such that the geneticallymodified T-cell expresses the CAR and the IL-10 polypeptide encoded bysaid first and second nucleic acid sequences respectively.
 125. Thegenetically modified T-cell of claim 124 wherein the first nucleic acidsequence and the second nucleic acid sequence are provided on a singlevector.
 126. The genetically modified T-cell of claim 125 wherein thevector is a plasmid.
 127. The genetically modified T-cell of claim 125wherein the vector is a viral vector.
 128. The genetically modifiedT-cell of claim 125 wherein the first nucleic acid sequence and thesecond nucleic acid sequence are each operably linked to atranscriptional and translational regulatory sequence capable ofdirecting the transcription and translation of the operably linkednucleic acid sequence in the genetically modified T-cell.
 129. Thegenetically modified T-cell of claim 125 wherein the first nucleic acidsequence and the second nucleic acid sequence are operably linked to asingle transcriptional and translational regulatory sequence capable ofdirecting the transcription and translation of the first and secondnucleic acid sequences in the genetically modified T-cell.
 130. Thegenetically modified T-cell of claim 128 wherein the vector is a viralvector.
 131. The genetically modified T-cell of claim 129 wherein thevector is a viral vector.
 132. The genetically modified T-cell of claim128 wherein the transcriptional and translational regulatory sequenceseach comprises a promoter wherein the promoter is a constituitivepromoter.
 133. The genetically modified T-cell of claim 128 wherein thetranscriptional and translational regulatory sequences each comprises apromoter wherein the promoter is an inducible promoter.
 134. Thegenetically modified T-cell of claim 129 wherein the transcriptional andtranslational regulatory sequence comprises a promoter wherein thepromoter is a constituitive promoter.
 135. The genetically modifiedT-cell of claim 129 wherein the transcriptional and translationalregulatory sequence comprises a promoter wherein the promoter is aninducible promoter.
 136. The genetically modified T-cell of claim 124wherein the CAR comprises a first nucleic acid sequence and the secondnucleic acid sequence are each provided on a separate vector.
 137. Thegenetically modified T-cell of claim 136 wherein the vector is aplasmid.
 138. The genetically modified T-cell of claim 136 wherein thevector is a viral vector.
 139. The genetically modified T-cell of claim136 wherein the first nucleic acid sequence and the second nucleic acidsequence are each operably linked to a transcriptional and translationalregulatory sequence capable of directing the transcription andtranslation of the operably linked nucleic acid sequence in thegenetically modified T-cell.
 140. The genetically modified T-cell ofclaim 136 wherein the first nucleic acid sequence and the second nucleicacid sequence are operably linked to a single transcriptional andtranslational regulatory sequence capable of directing the transcriptionand translation of the first and second nucleic acid sequences in thegenetically modified T-cell.
 141. The genetically modified T-cell ofclaim 139 wherein the vector is a viral vector.
 142. The geneticallymodified T-cell of claim 140 wherein the vector is a viral vector. 143.The genetically modified T-cell of claim 139 wherein the transcriptionaland translational regulatory sequences each comprises a promoter whereinthe promoter is a constituitive promoter.
 144. The genetically modifiedT-cell of claim 140 wherein the transcriptional and translationalregulatory sequences each comprises a promoter wherein the promoter isan inducible promoter.
 145. The genetically modified T-cell of claim 124wherein a nucleic acid encoding an IL-10 polypeptide encodes a maturehuman IL-10 polypeptide.
 146. The genetically modified T-cell of claim124 wherein the cell surface antigen present on the target cellpopulation is selected from the group consisting of CD19, CD20, CD22,ROR1, mesothelin, CD33/IL3Ra, c-Met, PSMA, glycolipid F77, EGFRvIII,GD-2, NY-ESO-1 TCR, MAGE A3 TCR, or any combination thereof.
 147. Thegenetically modified T-cell of claim 146 wherein the intracellularsignaling domain selected from the group consisting of the zeta chain ofthe T-cell receptor complex, the human CD3 zeta chain, CD3 δpolypeptide, CD3 Δ polypeptide, CD3 ε polypeptide, syk family tyrosinekinases, src family tyrosine kinases, CD2, CD5 and CD28.
 148. Thegenetically modified T-cell of claim 147, wherein the CAR furthercomprises a co-stimulatory domain.
 149. The genetically modified T-cellof claim 146, wherein the co-stimulatory domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2,CD5, ICAM-1, LFA-1 (CD11a/CD18), Lck, TNFR-I, TNFR-II, Fas, CD30, andCD40 domains.
 150. A method of treating a mammalian subject having acancer-related disease, disorder or condition, comprising administeringto the subject a therapeutically effective amount of a geneticallymodified T-cell transformed with a first nucleic acid sequence encodinga chimeric antigen receptor (CAR), wherein the CAR comprises: a) atleast one antigen-specific targeting region that specifically binds acell surface antigen present on the target cell population, b) atransmembrane domain, and c) an intracellular signaling domain, and asecond nucleic acid sequence, wherein the second nucleic acid sequencecomprises: a) a nucleic acid encoding a signal peptide (SP); and b) anucleic acid encoding an IL-10 polypeptide the nucleic acid encoding thesignal peptide being in frame with the nucleic acid sequence encodingthe IL-10 polypeptide; wherein said first and second nucleic acidsequences are operably linked to at least one transcriptional andtranslational regulatory sequence capable of directing the transcriptionand translation of a nucleic acid sequence in the genetically modifiedT-cell, such that the genetically modified T-cell expresses the CAR andthe IL-10 polypeptide encoded by said first and second nucleic acidsequences respectively.
 151. The method of claim 150 wherein the T-cellsare obtained from the subject, genetically modified ex vivo andreintroduced into the subject.
 152. The method of claim 150 wherein thewherein the cell surface antigen present on the target cell populationis selected from the group consisting of CD19, CD20, CD22, ROR1,mesothelin, CD33/IL3Ra, c-Met, PSMA, glycolipid F77, EGFRvIII, GD-2,NY-ESO-1 TCR, MAGE A3 TCR, or any combination thereof.
 153. The methodof claim 150 wherein the wherein the wherein the intracellular signalingdomain selected from the group consisting of the zeta chain of theT-cell receptor complex, the human CD3 zeta chain, CD3 δ polypeptide,CD3 Δ polypeptide, CD3 ε polypeptide, syk family tyrosine kinases, srcfamily tyrosine kinases, CD2, CD5 and CD28.
 154. The method of claim 150wherein the wherein the CAR further comprises a co-stimulatory domain.155. The genetically modified T-cell of claim 149, wherein theco-stimulatory domain is selected from the group consisting of CD28,CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1(CD11a/CD18), Lck, TNFR-I, TNFR-II, Fas, CD30, and CD40 domains. 156.The method of claim 150 wherein a nucleic acid encoding an IL-10polypeptide encodes a mature human IL-10 polypeptide.